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Stroke is a leading cause of death and the leading cause of adult neurological disability in Australia. 
The interventions currently available for the management of stroke include intravenous 
thrombolysis, thombectomy, decompressive hemicraniectomy, antithrombotic therapy, stroke unit 
care and rehabilitation. The aims of these interventions are to reduce the amount of damage caused 
by stroke and to support recovery. Currently, there is no method to reverse the damage caused by 
stroke. The pattern of functional recovery following stroke reveals a critical period of enhanced 
neuroplasticity. This period is a candidate therapeutic target for post-stroke neurological repair, 
either by increasing the degree of neuroplasticity that occurs or by extending the duration of 
enhancement. Experimental interventions that promise to enhance post-stroke neuroplasticity are 
being investigated. There is extensive evidence that functional recovery can be improved through 
interruption of endogenous inhibitory mechanisms, which include perineuronal nets (PNNs) and 
Nogo signalling. Chapter one outlines a review of the literature concerning the pathophysiology of 
ischaemic stroke, evidence in support of enhanced post-stroke neuroplasticity and evidence in 
support of potential therapies that target post-stroke neuroplasticity. This review forms the basis for 
the body of work described in this thesis. 
 
Cell-based therapy is one potential way of enhancing recovery from ischaemic stroke. Stem cell 
transplantation following stroke has resulted in functional improvements in pre-clinical studies. The 
mechanism of action underlying this effect is unclear, though it is thought to be through the 
paracrine secretion of neurotrophic cytokines and not through replacement of lost tissue. 
Intriguingly, both direct intracerebral transplantation and intravascular transplantation are 
efficacious. For transplanted stem cells to enter the brain from circulation, they must cross the 
blood-brain barrier (BBB). While this has been shown to occur, the mechanism through which stem 
cells cross the BBB has not been fully elucidated. Chapter two demonstrates that human dental pulp 
stem cells (DPSC) can increase BBB permeability through the expression of vascular endothelial 
growth factor. DPSC conditioned medium caused an increase in permeability of an in vitro model of 
the BBB and this effect was reversed by blocking the VEGF receptor. These results support the 




One of the hypothetical mechanisms of action for cell-based therapy is the interruption of PNNs. 
These are a specialised form of dense ECM within the adult brain and spinal cord that form part of 
an endogenous system for the inhibition of neuroplasticity. Digestion of PNNs through 
administration of a bacterial enzyme has been shown to improve outcomes following neurological 
insults, including stroke. Chapter three demonstrates that DPSC express soluble products that digest 
PNNs. Application of DPSC conditioned media to in vitro PNN models and brain slices resulted in 
decreased staining of PNNs. Additionally, DPSC were shown to express active matrix 
metalloproteinase-2, which digested aggrecan, one of the main PNN components. These results 
suggest that interruption of PNNs may be a mechanism through which cell-based therapy enhances 
recovery in the setting of ischaemic stroke. 
 
As PNNs are a target for future stroke therapies, it is important to understand the endogenous 
response of PNNs to stroke. There is evidence in the literature that PNNs are temporarily 
downregulated after stroke. Numerous studies have demonstrated the temporary downregulation 
of PNNs after stroke through general staining for the carbohydrate components of PNNs and some 
of the protein components. However, PNNs are not homogeneous throughout the central nervous 
system and variations in their composition affect their ability to inhibit neuroplasticity. The response 
of PNNs to stroke has not yet been fully described. Chapter four addresses this by characterising the 
expression profile of several PNN components in a mouse stroke model. Following photochemical 
infarction, there was a temporary decrease in staining of cartilage link protein-1, aggrecan and WFA-
binding glycans in the cortex. This effect was more pronounced in the region of the cortex 
contralateral to the lesion. Additionally, 4-O-sulfated chondroitin, which is the most inhibitory PNN-
associated carbohydrate component, was temporarily enriched in the ischaemic border zone. This 
pattern of regulation may underlie the post-stroke critical period enhanced neuroplasticity. 
 
The development of new stroke treatment strategies targeting neuroplasticity is dependent on 
preclinical in vivo studies. To ensure that pre-clinical studies are mutually comparable, there is a 
need for a standardised protocol for modelling human stroke. The requirements of this model are 
that it be reproducible, technically accessible, it must minimise animal suffering and it must 
accurately model chronic stroke in humans. Many studies use young animals, which recover rapidly 
and more completely from ischaemic stroke. This is not appropriate for testing stroke therapies for 
humans as stroke risk is correlated with age. Additionally, middle cerebral artery occlusion is still 
considered the gold standard for modelling stroke. This is biologically accurate, but is technically 
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difficult, results in variable infarcts and is associated with relatively high mortality and suffering. 
Chapter five outlines a preliminary study towards the development of a standardised protocol for 
chronic stroke in aged mice. A photochemical induction method was used, which resulted in 
reproducible, targeted lesions that were detectable by MRI. This method produced detectable 
dysfunction of the affected limb at early time points only. These results suggest that further 
optimisation needs to be done in developing a standardised model of chronic stroke. 
 
4 
Chapter 1: Introduction 
 
1.1: Stroke 
Brain tissue is highly energetic, dependent on oxidative phosphorylation for energy and has limited 
collateral circulation. Because of this, the brain is susceptible to damage following loss of perfusion. 
A stroke occurs when a decrease in perfusion is severe enough to result in a permanent lesion1.  The 
two main subtypes of stroke are cerebral ischemia, which accounts for 87% of all stroke cases and 
haemorrhagic stroke, which accounts for 13% of stroke2. Ischaemic stroke can be further divided 
into large vessel and lacunar infarcts. The latter occur within white matter and present as typical 
clinical syndromes, though many may be silent infarcts. Lacunar infarcts have been identified in 
approximately 15% of patients presenting with first stroke3. While ischaemic stroke is more 
common, the 30-day mortality rate associated with it is only 11-15%, as compared with 37% for 
haemorrhagic stroke4. Because of this, many people live for years with chronic cognitive and 
sensory-motor disability as a consequence of ischaemic stroke5. 
Ischaemic stroke refers to a permanent cerebral lesion resulting from the occlusion of a cerebral 
artery. This occlusion may be the result of local atherosclerotic plaque rupture and thrombosis or 
the result of an embolism generated distally6. The most common sites for ischaemic stroke are the 
branches of the middle cerebral arteries (MCA)7. The symptoms and signs of an ischaemic stroke are 
directly related to the vascular territory involved and the function of the brain region that it serves.  
Most ischaemic lesions have cortical involvement with obvious impairment to sensory, motor and 
cognitive faculties8. 
The acute pathophysiology of a cerebral infarct is characterised by the ischaemic cascade. An initial 
drop in perfusion causes failure of ion pumps, loss of membrane potential and subsequent 
uncontrolled depolarisation. The activation of voltage-gated ion channels causes the inappropriate 
release of excitatory neurotransmitters, including glutamate. Due to continued energetic failure, 
glutamate reuptake is also inhibited. This results in an accumulation of glutamate within the synaptic 
cleft. Glutamate excitotoxicity causes an uncontrolled cytoplasmic influx of electrolytes9,10. 
Inappropriate glutamate receptor activation also directly causes reactive oxygen species (ROS) 
production, resulting in damage to surrounding tissue11. Increased cytoplasmic osmotic pressure 
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leads to cytotoxic oedema and cell lysis12. Tissue necrosis leads to ROS production, causing further 
cell death and delayed inflammation. 
Ischaemic damage begins at the infarct core, which represents tissue supplied exclusively by the 
occluded vessel. The ischaemic core is surrounded by a penumbra of poorly perfused but viable 
tissue13,14. Untreated, the penumbra may continue to transform into ischaemic tissue due to ongoing 
excitotoxicity, ROS production and inflammation. The rate of penumbral transformation is highly 
variable between individuals and is mainly dependent on the degree of collateral circulation 
available to support penumbral tissue15. Additionally, factors such as comorbid metabolic disease 
and acute hyperglycaemia increase penumbral transformation rate16, while pre-stroke physical 
activity is protective against rapid infarct growth17. Typically, penumbral transformation within the 
acute phase of stroke is rapid, with a loss of approximately 1.9 million neurons per minute18.  
Significant penumbral transformation occurs within the first 4 hours19, however penumbral tissue 
has been detected up to 24 hours after an occlusion in rodents20. Furthermore, measurement of 
penumbral volume in humans by perfusion/diffusion weighted MRI mismatch has demonstrated 
that in some patients, the penumbra may persist up to 48 hours post-stroke. This is an important 
concept because it suggests that some patients may respond favourably to delayed reperfusion. 
Reperfusion may be brought about either by intervention or endogenous thrombolysis. Spontaneous 
endogenous reperfusion may take hours to days and most salvageable tissue will not survive this 
amount of time21.  
A major therapeutic target for current stroke therapies is acute reperfusion. Current evidence-based 
management includes antithrombotic medication, stroke unit care, decompressive 
hemicraniectomy, thrombectomy and intravenous thrombolysis22–24. Further to this, primary 
prevention of stroke guided by modifiable risk factors is a significant clinical target25. In particular, 
smoking cessation, blood pressure control, management of dyslipidaemia and glycaemic control 
prevent stroke in part by promoting vascular endothelial function. The efficacy of these treatments 
and management strategies lies in attenuating the damage cause by stroke and in preventing the 
occurrence of future stroke. 
The main limitation of stroke treatment is that intravenous thrombolysis and thombectomy are only 
effective when provided before complete infarction has occurred. Intravenous thrombolysis also 
carries a significant risk of haemorrhage26. As a result, intravenous thrombolysis is only indicated for 
patients who can receive it within 4.5 hours of symptomatic onset27 and thrombectomy has only 
shown efficacy when received within the first 24 hours28. Despite the removal of barriers to care and 
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reductions in time-to-treat, many patients are still not eligible for reperfusion29. There is a need for 
new ways to treat stroke in the sub-acute and chronic phases.  
One mode for potential stroke treatment is neuroprotection, a paradigm that has attracted 
extensive research over the last four decades. While the conventional ways of managing acute 
stroke focus on salvaging penumbral tissue by establishing reperfusion, neuroprotective strategies 
target the biochemical processes that underlie the ischaemic cascade. One of the main targets of 
neuroprotection is glutamate excitotoxicity. Animal studies have identified a plethora of treatments 
that improve outcomes by blocking NMDA receptors30–34, inhibiting glutamate indirectly35 or by 
providing magnesium to encourage NMDA inactivation36. Similarly, targeting apoptotic signalling 
through calcium channel blockade has demonstrated promising preclinical results37. The third major 
target of neuroprotection is the ROS produced downstream of excitotoxicity; several ROS scavengers 
have demonstrated efficacy in animal stroke models38,39.  
Despite the positive results of animal studies, neuroprotective agents have not demonstrated 
efficacy in phase 3 clinical trials and thus none have been translated40. It is important to understand 
the reasons for this failure in translation when considering potential stroke treatments of other 
modalities. One reason is that the animal models used in pre-clinical studies did not appropriately 
model stroke in humans. For example, due to cost and time limitations, drugs were often tested in 
young and otherwise healthy animals. However, we know that in humans the risk of stroke increases 
with age and often occurs in the context of significant comorbidities. Another factor is that stroke 
models often create discreet and standardised lesions, which is important because it means that 
small effect sizes can be detected with reasonable sample sizes. However, in humans, stroke is a 
highly heterogeneous syndrome and clinical trials are therefore unable to detect such small benefits. 
A third putative cause for failure in translation is that animal stroke models were treated in the 
hyper-acute phase of stroke pathogenesis, whereas humans enrolled in clinical trials often 
experienced a delay41. This is important because the mechanism of neuroprotection relies on the 
salvaging of penumbral tissue and is therefore subject to similar time constraints as reperfusion 
therapies. One conclusion that may be drawn from this is that hypothetical neuroprotective 
strategies may be used as an adjuvant to improve the efficacy of reperfusion therapies but are 




In the wake of extensive research into neuroprotection, we are still left with a dearth of 
interventions for sub-acute or chronic stroke. Therefore, another possible approach to filling the 
need for new stroke treatments is to target adult neuroplasticity. 
 
1.2: Neuroplasticity 
1.2.1: Overview of neuroplasticity 
Cognition and behaviour are emergent properties of the immensely complex network of the brain. 
While development clearly provides a scaffold and many innate circuits for primal behaviours and 
reflexes, complex behaviours and the circuits that create them must be built and refined in an 
experience-dependant way. Neuroplasticity describes the changes in anatomy and electrophysiology 
that underlie learning in the brain. 
While the concept of neuroplasticity was first explored by Ramón y Cajal42, the idea that physical 
changes to brain structure underlie learning gained traction with Hebb’s postulate in the mid-
twentieth century. Prior to this, it was widely held that the adult human brain was anatomically 
static. Hebb's postulate states that the weights of connections between neurons are increased when 
one neuron is involved in causing an action potential in another43. This model is summarised by the 
adage 'neurons that fire together, wire together'. Repetitive communication between neurons in this 
manner results in the evolution of coherent networks. Improvements of this model led to the 
development of predictive models of neuroplasticity and in silico simulation of neural networks44,45. 
Neuroplasticity is achieved by creating new synapses and changing the weights of existing synapses. 
One of the main mechanisms for learning and memory is long term potentiation (LTP), a process 
whereby the weights of existing synapses are altered. When synchronous action potentials occur in 
two synapsed glutaminergic neurons, N-methyl-D-aspartate (NMDA) receptors in the postsynaptic 
membrane become activated. This increases the sensitivity of the post-synaptic neuron to 
depolarisation of the presynaptic neuron. Repeated transmission through a synapse over time 
results in translocation of glutamate receptors to the post-synaptic membrane, resulting in a long-
term increase in synaptic strength28, see 29. 
The anatomic changes underlying neuroplasticity are axonal sprouting, dendritic arborisation and 
synaptogenesis. These processes allow for the creation of experience-dependent network traces. 
Synapses that remain unused decay, while those that frequently transmit signals are reinforced by 
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LTP. Neurogenesis allows for the introduction of new nodes into existing networks. This process 
predominantly occurs during development, although some adult neurogenesis has been observed, 
particularly in the hippocampus48 and subventricular zone. 
The degree of neuroplasticity in mammalian brains is variable. Childhood is spanned by critical 
periods, which are times during which the brain is highly plastic and easily reorganises in response to 
environmental stimuli. This is the time during which children learn language, learn to recognize 
objects, learn how to walk and generally adapt to interact with their environment. The timing of 
critical periods varies for different systems. For example, the critical period for language ends 
sometime between 5 years of age and puberty49, whereas the visual critical period ends at 
approximately 30 months of age50. If the required environmental stimulation is not received during 
the critical period for a skill, then that skill may never be fully acquired. This was demonstrated in 
the famous study by Hubel and Wiesel, which showed that monocular deprivation in infant cats for 
the duration of the critical period resulted in permanent monocular blindness51.  
Neuroplasticity in the adult human brain has been measured in response to several types of 
environmental stimulation. Structural changes can be seen on magnetic resonance imaging (MRI) 
following the acquisition of new skills, including juggling, ballet, Morse code and learning a second 
language52–55. Importantly, the changes were detected in brain regions responsible for the new skill. 
More recent investigations using functional MRI and tractography have demonstrated increased 
axon density in correlation with skill acquisition56,57. 
The degree of neuroplasticity available can be influenced by environmental factors. In animals, 
stress causes a reversible reduction in the length of hippocampal dendrites and a consequent 
reduction in the number of synapses they form58,59. This causes a temporary impediment to learning 
during protracted periods of stress. Conversely, voluntary aerobic exercise enhances learning and 
neuroplasticity60,61. 
 
1.2.2: Post-Stroke Neuroplasticity 
A parallel can be drawn between the timing of behavioural recovery after stroke and critical periods 
in children. In the months following stroke, skill reacquisition occurs rapidly. While rehabilitation 
may result in improvements years after a stroke, evidence suggests that most skill reacquisition 
occurs within the first six months62–64. This period of active neuroplasticity is a promising target for 
new stroke treatments (Figure 1). 
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It has long been observed that many stroke patients will undergo a period of spontaneous functional 
recovery 65. It may be argued that this recovery is the result of normal training effects, independent 
of the stroke. However, the EXCITE stroke trial presented compelling evidence that the timing of 
rehabilitation influences the total amount of recovery achieved after 24 months. Patients who 
received rehabilitation from 0-6 months achieved greater recovery than those who received the 
same rehabilitation after a three-month delay66. One important caveat to this is that the AVERT trial 
determined that high-dose rehabilitation within the first 24 hours of a stroke resulted in poorer 
functional outcomes and no reduction in mortality when compared with conventional practices67. 
This study raised concerns that very early high-dose rehabilitation may be harmful, especially in 
patients with haemorrhagic stroke. While plausible mechanisms may be advanced to explain this 
effect, it seems unlikely to be related to neuroplasticity. 
Additionally, data from rodent stroke models has demonstrated accelerated learning in tasks 
involving the unaffected forepaw68. This suggests that following an ischaemic insult, distant areas of 
the brain may also experience an increase in neuroplasticity. Another interpretation is that midline-
crossing fibres originating from the infarcted cortex convey functional plasticity to the ipsilesional 
forepaw. The way to differentiate these would be to assess neuroplasticity in a more distant area, 
such as the ipsilesional hindpaw, or to assess neuroplasticity in a different modality than that 
controlled by the lesioned cortex, such as fear conditioning.  
An interesting outcome of the research into heterogeneous regions of neuroplasticity following 
stroke is that compensation through neuroplasticity in the contralesional hemisphere paradoxically 
results in poorer functional outcomes69. In one study, stroke patients with increased conduction 
from the affected leg to the ipsilateral (non-stroke) motor cortex were shown to have poorer control 
of both limbs70. The authors offered that this effect may be due to the generation of uncoordinated 
and conflicting flexor-extensor signals in the non-lesioned cortex, which may occur due to lack of 
inhibition from the damaged cortex. Another hypothesis is that alternative ipsilateral motor 
pathways are more active following more severe damage to primary motor pathways, and that 
secondary pathways only partially compensate for this damage71. The clinical implication of this is 
that if contralesional neuroplasticity is inherently maladaptive, then treatment models targeting 
neuroplasticity will need account for this. For example, targeted approaches to increasing 
neuroplasticity may be possible.  
Evidence for post-stroke structural neuroplasticity comes largely from rodent studies. Ischaemic 
injury increases the rate of hippocampal neurogenesis and some newly generated neurons 
differentiate and integrate within the brain72. Furthermore, stroke results in a temporary period of 
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dendritic outgrowth in the contralesional cortex73 and a consequent increase in synaptogenesis74,75. 
This is likely to be caused by an upregulation of growth-promoting neurotrophic factors, including 
brain-derived neurotrophic factor (BDNF)76, basic fibroblast growth factor (bFGF)77–79 and growth-
associated protein 43 (GAP43)75,80. Another possible cause for post-stroke neuroplasticity is the 
























Figure 1: Underlying recovery from ischaemic stroke is a period of enhanced neuroplasticity. 
Neuroanatomic reorganisation occurs downstream of neurotrophic factor upregulation and 
perineuronal net downregulation. Rehabilitation has its greatest effect during this time and only 
limited recovery of function is possible beyond it.  
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1.3: CNS Inhibitors of Neuroplasticity 
Compared with those of infants and children, adult brains are relatively resistant to extensive 
reorganisation. As a result, adults who suffer ischaemic damage or other CNS insults recover to a 
much lesser extent than children81. Several mechanisms have been identified that are responsible 
for the non-permissive nature of the adult brain to neuroplasticity. The two major systems 
addressed in this review are the neuron-associated perineuronal nets (PNNs) and the 
oligodendrocyte-associated Nogo proteins (Figure 2). Other mechanisms that are not evaluated here 
include negative axonal guidance through semaphorin-plexin interactions and the glial inhibitors of 




Figure 2: Two major mechanisms for inhibition of neuroplasticity within the central nervous system 
are perineuronal nets and the Nogo pathway. Perineuronal nets inhibit plasticity through steric 
hindrance, growth factor sequestration, receptor immobilisation, presentation of semaphorins and 
interactions with the neuronal receptors S1PR2, Receptor type protein tyrosine phosphatase (RPTP)σ 
and LAR. The Nogo proteins are expressed intracellularly and on the membranes of oligodendrocytes, 
which form the myelin sheaths surrounding axons. Nogo acts through interactions with the neuronal 
receptors S1PR2, NgR1 and PirB. Both systems converge on cytoskeletal reorganisation, leading to 
axon repulsion and growth cone collapse. 
 
1.3.1: Perineuronal Nets 
1.3.1.1: Overview of perineuronal nets 
PNNs are complex reticular structures surrounding the soma and proximal neurites of 
subpopulations of neurons in the brain and spinal cord (Figure 3). These structures were first 
described by Camillo Golgi, who saw them as an extracellular counterpart to the Golgi apparatus82. 
Early hypotheses were that PNNs represented a branching mesh of axon terminals, that they were a 
component of the blood-brain barrier and that they were staining artefacts82,83. PNNs are now 
understood to be a specialised type of ECM, which has principal functions in development and in 
regulating adult neuroplasticity.  
Microscopically, PNNs appear as a scale-like mesh of dense ECM surrounding neuronal cell 
membranes and interrupted by axonal and glial contacts84. PNNs are predominantly distributed 
around parvalbumin-expressing GABAergic interneurons and few pyramidal cells of the primary 
motor and sensory cortices, the hippocampus and purkinje neurons of the cerebellar cortex85–88. 
At a molecular level, PNNs are composed of chains of hyaluronan (HA), which are tethered to 
neuronal cell membranes by hyaluonan synthase (HAS). Chondroitin sulfate proteoglycans (CSPGs) 
including aggrecan, versican, brevican and neurocan are bound by cartilage link protein (Crtl-1) or 
brain link protein (Bral-1) at their N-termini. These link proteins are in turn bound to HA. Tenascin R 
(Tn-R) binds the C-termini of up to three CSPG molecules89,90. The relative amounts of each CSPG 
varies in different locations within the CNS91. CSPGs themselves are composed of a core protein 
covalently bound to glycosaminoglycan (GAG) side chains92, which are responsible for much of the 
biological function of PNNs93. In particular, GAG sulfation state is related to function, with 4-O-
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sulfation (C4S) producing inhibition to neurite outgrowth94 and 6-O-sulfation (C6S) stimulating 
neurite outgrowth95,96. 
One of the chief observations that has led to the current understanding of the function of PNNs is 
the coincidence of PNN maturation and the termination of critical periods84,97. The components of 
PNNs are not assembled concurrently, but rather sequentially. At birth, primordial PNNs are 
composed only of HA and resemble loose ECM. The ECM does not condense into mature PNNs until 
aggrecan, TN-R and link proteins are expressed, which in mice occurs 6-21 days postnatal98,99. 
Another observation is that PNN expression in songbirds correlates with the critical period for song 
learning in age-limited species100 and with seasonal periods of song learning in species that learn 
new songs in maturity101. As PNNs mature, their ratio of C6S:C4S also changes. Primordial PNNs 
present high levels of the permissive C6S, which is replaced by the inhibitory C4S in maturity95,102. 
This strongly suggests that PNNs are one of the molecular mechanisms responsible for limiting adult 
neuroplasticity. 
For PNN maturation to take place, specific external stimulation must occur during the critical 
periods. In mice, whisker trimming results in sensory deprivation of the barrel cortices. If whiskers 
are trimmed for the duration of the critical period, then mature PNNs fail to develop in the affected 
barrel cortex99. Restoration of sensory input after critical period termination is not sufficient to 
stimulate maturation of PNNs103. Likewise, depriving juvenile songbirds of a tutor delays the 
development of PNNs in the brain regions responsible for song100. It is unclear how this reconciles 
with the classical understanding that neuroplasticity is limited after critical period termination 
despite sensory deprivation51. It is likely that redundant mechanisms are responsible for limiting 
critical periods, so perhaps PNN attenuation in sensory deprivation is not sufficient to extend critical 
period plasticity indefinitely.The mechanisms of action by which PNNs cause inhibition of 
neuroplasticity have not been fully elucidated, though four main hypotheses exist. 1) By surrounding 
the soma and proximal neurites, PNNs form a barrier to new synaptic contacts being made104,105. 2) 
PNNs inhibit neurite outgrowth through receptor interactions. CS itself has an affinity for receptor 
protein tyrosine phosphatase σ (RPTPσ)106, leukocyte common antigen-related phosphatase (LAR)107 
and Nogo receptor 1 (NgR1)108. Moreover, PNNs have an association with other inhibitory 
molecules109. Notably, the chemorepulsive axon guidance molecules semaphorin 3A110,111 and 
semaphorin 5A112 colocalise with PNNs and appear to form an active component. 3) PNNs sequester 
growth-promoting molecules, including laminin113 and heparin binding growth factors, preventing 
their activity109. 4) PNNs regulate the mobility of glutamate receptors, which in turn regulates 
excitatory activity and synaptic plasticity114 (Figure 2). 
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It is unclear why inhibition of plasticity around the subpopulation of neurons associated with PNNs is 
sufficient to control functional neuroplasticity. The two possibilities are 1) PNNs surround enough 
neurons to affect global neuroplasticity or 2) The neurons associated with PNNs are somehow 
specialised to act as gatekeepers to neuroplasticity. Whichever hypothesis best explains the effect, 
the empirical findings that link PNNs with inhibition of neuroplasticity stand to suggest that the 


























Figure 3: Perineuronal nets ensheath subsets of neurons in the mammalian brain, predominantly the 
parvalbumin-expressing GABAergic interneurons. At a microscopic level, PNNs surround the soma, 
proximal dendrites and axon initial segments, with discontinuities over postsynaptic membrane 
regions. At a molecular level, PNNs are a lattice of glycosaminoglycans (GAG). Long chains of 
hyaluronan are bound to neuronal membranes by hyaluronan synthase. Chrondroitin sulfate 
proteoglycans (CSPGs) are bound to hyaluronan through interactions with cartilage link protein and 
are stabilised through interactions with tenascin-R. The sulfation state of the CSPG side chains 
determines the inhibitory activity of PNNs. C6S is permissive to neuroplasticity while C4S is inhibitory. 
 
1.3.1.2: Disruption of Perineuronal Nets Enhances Neuroplasticity 
Disruption of PNNs in mature animals results in a degree of neuroplasticity reminiscent of the critical 
periods. One way of disrupting PNNs is with direct administration of the bacterial enzyme ABC 
chondroitinase (chABC), which digests GAG chains in both PNNs and loose ECM. In adult animals 
who were deprived of visual sensation during the critical period, treatment with chABC re-
establishes ocular dominance plasticity and leads to normal development of visual acuity with 
neuroanatomic correlates115,116. 
Administration of chABC in rodent models of spinal cord injury (SCI) results in extension of axons117 
from the transected spinal cord and significant functional recovery118–121. This is relevant because the 
spinal cord presents the same inhibition to neurite outgrowth as the brain. Notably, optimum 
recovery was demonstrated when treatment was followed with task-specific rehabilitation118. PNN 




Transgenic mice with abnormal PNNs also present with increased adult neuroplasticity. The link 
protein Crtl-1 is a critical component of PNNs122. Animals deficient in link proteins Crtl-1 and Bral2 
present with globally attenuated PNNs and extended critical periods, spinal cord plasticity and rapid 
compensation following vestibular deafferentation123,124. Mice deficient in aggrecan likewise present 
without mature PNNs and while one may hypothesize that this would extend critical periods, such 
studies have not been published to date. However, mice deficient in RPTPσ, a receptor for CS, show 
increased axonogenesis following SCI106,125. 
Disruption of PNNs has demonstrated efficacy in the treatment of ischaemic stroke in preclinical 
studies. Recovery of sensory-motor function has been obtained by treatment with chABC in the 
spinal cord126,127 and the ipsilesional cortex128,129. The neuroanatomical correlates of this enhanced 
functional plasticity include growth of midline-crossing axons from the contralateral homotopic 
region126 and branching of neurites in the region surrounding the infarct127. Disinhibition of 
neuroplasticity with chABC also had the effect of protecting distant brain regions from delayed 
secondary damage following ischaemic stroke129. The mechanism for this is unclear, but it may be 
that denervated distant regions are able to be salvaged by forming new synapses with unaffected 
regions.  
Another important concept is that combining chABC treatment with rehabilitation has a synergistic 
effect on functional recovery and neuroanatomical plasticity. In two recent studies, rat models of 
focal motor cortex stroke were treated with perilesional128 or intrathecal127 injections of chABC, 
which was combined with a rehabilitation schedule. In the first study, task-specific rehabilitation was 
provided concurrently with chABC as training in a skilled reach behaviour test. This combination 
resulted in significant improvement in performance of the behaviour test128. The second study 
compared the effect of combining intrathecal chABC with early task-specific rehabilitation, with late 
rehabilitation and with no rehabilitation. While all treatment arms resulted in significant 
improvement in skilled reach performance, the delayed rehabilitation schedule was superior127. This 
is consistent with the hypothesis that chABC treatment opens a window for plasticity that must be 
guided by Hebbian mechanisms. 
 
1.3.1.3: Endogenous Regulation of Perineuronal Nets 
The structure and composition of PNNs in the mature CNS is not static, but varies in response to 
external factors that are known to stimulate neuroplasticity. Examples of stimuli that trigger 
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neuroplasticity are neurological insult, exposure to novel sensory stimulation and exercise. The co-
variation of PNN expression and neuroplasticity in these situations suggests a role for PNN 
regulation in facilitating learning and skill acquisition in the adult brain.  
One model of adult neuroplasticity is the recovery of postural reflexes following vestibular 
deafferentation. In animal models, unilateral ablation of the vestibular apparatus has been shown to 
result in a loss of proprioception that can be measured as postural dysfunction. Recovery of postural 
reflexes over time has been shown to result from compensatory neuroanatomic reorganisation, 
including axonogenesis, synaptic plasticity130 and neurogenesis131  within the vestibular nuclei. One 
study in mice has demonstrated that wisteria floribuna agglutinin (WFA)-staining PNNs were 
downregulated in both vestibular nuclei and this effect was correlated with structural remodelling as 
well as functional recovery124. 
Voluntary aerobic exercise has also been demonstrated to enhance adult neuroplasticity. An 
extensive systematic review on the effect of exercise on post-stroke neuroplasticity indicated that 
exercise enhanced functional neuroplasticity through synaptic and dendritic plasticity132. A more 
recent study not included in the systematic review showed that voluntary exercise in rats resulted in 
a decrease in expression of WFA-staining PNNs in the hippocampus133. As the hippocampus is 
involved in memory consolidation, this suggests that PNN downregulation may be a mechanism 
through which exercise stimulates neuroplasticity. 
As discussed in section 1.2.1, deprivation of visual stimulation during the critical period results in 
persistent blindness51. A study in rats has shown that providing novel sensory input through 
environmental enrichment stimulated neuroplasticity in the visual cortex, resulting in recovery of 
visual acuity134. Furthermore, it was shown that WFA-stained PNNs were also downregulated in the 
visual cortex. This has two important implications: 1) A degree of neuroplasticity previously not 
thought to occur in adulthood can be achieved through environmental stimulation and 2) PNN 
downregulation may underlie part of this effect. 
It has also become apparent that modifications to PNNs are an important characteristic of stroke 
pathogenesis and recovery. Immediately following stroke, the ischaemic, perilesional and associated 
distant brain regions showed a decrease in WFA staining, lectican core proteins and link proteins135–
139 along with a loss of the reticular organisation of PNNs in those areas137,140. At the same time, 
human brain tissue showed an increase in hyaluronan staining up to 37 days post-stroke, which is 
thought to be related to increased turnover of hyaluronan in the brain ECM141. These alterations in 
PNN expression return to baseline by around 30 days post-stroke135 in animals, and may remain 
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months after stroke in humans140. These data suggest that the period of enhanced plasticity 
experienced after stroke is related to the alteration of PNNs and plasticity, both in areas surrounding 
the stroke and distant contralesional regions. A summary of these studies can be found in Figure 4. 
Many studies did not report on PNN expression in the contralesional hemisphere and some used the 
contralesional hemisphere as a control136,137. This is flawed because it assumes that stroke does not 
influence PNN regulation in regions unrelated to the infarct. Of the studies that did address the 
contralesional cortex, one found a decrease in WFA staining 24 hours post-infarct, but not aggrecan 
or brevican135, whereas another found no change in contralesional WFA staining at this time point139. 
In these studies, contralesional PNNs were identified only by their CSPG components (WFA staining, 
aggrecan and brevican). To date, PNN alteration in the contralesional hemisphere more than 24 
hours post-infarct has not been reported. 
Interestingly, post-stroke changes in the structure and distribution of PNNs are influenced by 
concurrent environmental stimulation. Two studies have demonstrated that post-stroke 
downregulation of PNNs was further enhanced by housing rats in enriched environments. 
Quattromani et.al.142 showed that enriched housing resulted in significantly reduced PNNs 
throughout the ipsilesional hemisphere but not the contralesional hemisphere at seven days post-
infarction. Madinier et.al.142 demonstrated an association between enriched housing and PNN 
downregulation throughout the ipsilesional cortex 63 days post-infarction. This indicates that 
environmental enrichment not only caused a greater degree of PNN downregulation, but also 
extended the period of PNN downregulation beyond what was seen in studies without 
environmental enrichment. Both studies were appropriately controlled with sham stroke animals as 
opposed to controlling with the contralesional hemisphere. However, only aggrecan was assessed as 
a PNN marker, meaning that changes in expression of other PNN components were not measured.  
These results suggest that the interrelationship between PNNs, environmental stimulation and 
neuroplasticity is such that endogenous PNN modulation is dependent on environmental stimulation 
and artificial degradation of PNNs requires environmental stimulation to cause functional 










Figure 4: A summary of the studies that investigate the post-stroke regulation of PNN components. 
Results reported from studies indicated by * were qualitative. ↑ indicates a reported increase in 




1.3.2.1: Overview of Nogo Signalling 
The Nogo proteins are myelin-associated inhibitors of neurite outgrowth that play a key role in 
regulating adult neuroplasticity. The therapeutic potential of targeting the neurite outgrowth 
inhibitory activity of Nogo was first explored in relation to its role in recovery from SCI. Treatment 
with anti-Nogo-Antibodies and Nogo receptor antagonists produces improved locomotor recovery 
and growth of transected axons following experimental models of SCI143–145.  
There are three Nogo isomers, and of these, Nogo-A is the most well-characterised. Nogo-A is a 
transmembrane protein with two extracellular active domains: Nogo-66 and Nogo-A-∆20. Nogo-66 is 
a 66-amino acid loop towards the C terminal of Nogo A that is also conserved in Nogo-B and -C. 
Nogo-A-∆20 is located towards the N-terminal and is specific to Nogo-A (Figure 2). 
In the adult brain, Nogo-A is primarily expressed by dorsal root ganglion neurons146, 
oligodendrocytes147 and immature neurons in the dentate gyrus148. The majority of Nogo-A is 
intracellular and associated with the endoplasmic reticulum149–152, though it is also located in the 
paracellular layer of the myelin sheath147. During development, Nogo-A is expressed by postmitotic 
neurons in the cortex, cerebellum and spinal cord147. This early expression pattern is thought to 
reflect a role in guiding the migration of neuroblasts in the developing CNS. 
The neurite outgrowth inhibitory activity of Nogo-A is mediated by three neuronal receptors: Nogo 
Receptor 1 (NgR1), Sphingosine-1 Phosphate Receptor-2 (S1PR2)153 and Paired Immunoglobulin-like 
Receptor B (PirB) (Figure 2). NgR1 and PirB are activated by the common active domain Nogo-
66146,154 and by PNN-associated CSPGs108. S1PR2 is a G protein-coupled receptor that is specific to the 
Nogo-A isomer153. The activation of NgR1 and S1PR2 converges on the RhoA/ROCK signalling 
pathway, which inhibits neurite outgrowth through cytoskeletal reorganisation155. Nogo-A-∆20 has 
also been shown to decrease expression of mTOR, which is known to regulate cellular growth 156,157. 
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1.3.2.2: Nogo Antagonism Promotes Neuroplasticity 
Inhibition of Nogo-A activity has been achieved in experimental stroke models by several 
mechanisms. The earliest and most extensively characterised of these is IN-1158, a monoclonal 
antibody with affinity for the Nogo-A-∆20 domain that inhibits the action of S1PR2 but not NgR1159. 
Other immunotherapeutic agents include 11C7144 and 7B12160, which are Nogo-A specific 
monoclonal antibodies and 7E11, a monoclonal antibody against NgR1161. A soluble protein 
antagonist of the NgR1 receptor, NgR(310)Ecto-Fc, has been demonstrated to exhibit similar 
plasticity-promoting effects to monoclonal antibodies162. Disruption of the Nogo signalling 
mechanism has also been achieved in transgenic animals deficient in NgR1 and NogoA/B162. 
The efficacy of anti-Nogo therapy has been tested on a broad variety of functional deficits in animal 
models. Significant improvements in skilled sensory-motor function have been reported in animals 
treated with IN-1, 11C7, NgR(310)Ecto-Fc and 7B12 following experimental stroke160,162–165. Animals 
receiving IN-1, NgR(310)Ecto-Fc and animals deficient in NogoA/B or NgR1 recovered coordination 
more rapidly and to a greater extent than control animals162. Anti-Nogo-A and anti-NgR1 
immunotherapy also resulted in improved recovery of spatial memory166 and reversed visuospatial 
neglect167. 
Nogo pathway inhibition promotes an enhancement of neuroplasticity in sensory-motor and 
cognitive systems. Several studies have reported that animals exhibiting improved functional 
recovery after anti-Nogo treatment also presented with an increase in the number of axons crossing 
from the homotopic cortex contralateral to the lesion and supplying the denervated corticospinal 
and rubrospinal tracts160,162–165,167,168. The responsibility of these newly generated axons for 
functional recovery was strongly supported by Brenneman et.al. 167, who demonstrated that corpus 
callosotomy reversed improvements made in hemispatial neglect due to anti-Nogo treatment. 
Furthermore, the excellent study by Wahl et.al. 165 described the development of two models for the 
inducible, selective blockade of midline-crossing axons. Blockade of these fibres temporarily 
reversed the improvements in sensory-motor function in animals treated with IN-1. 
In addition to axonogenesis, anti-Nogo treatment in animal models of stroke has demonstrated an 
increase in dendritic tree complexity in the contralesional homotopic cortex169 and somatotopic 
reorganisation of midline-crossing axons terminating in the pons170. This suggests that the novel 
neurite outgrowth caused by anti-Nogo treatment is directed and functionally relevant. 
 
23 
As anti-NogoA antibody treatment improves recovery of spatial memory following stroke, 
hippocampal plasticity was hypothesized as a possible mechanism166. Moreover, NgR1 activation has 
been shown to inhibit neural stem cell proliferation in the subgranular zone and S1PR2 activation 
increases migration of neuroblasts in the rostral migratory stream171. However, treatment with 11C7 
following stroke does not result in any change in neuronal proliferation in the subgranular zone, 
accumulation of new neurons in the granule cell layer148 or any change in the mobilisation or 
migration speed of subventricular zone neuroblasts172.These data suggest that enhancement of 
neuroanatomical plasticity in the hippocampus is not a mechanism by which anti-Nogo therapy 
produces its effect. 
It has emerged that the timing of treatment relative to the stroke and relative to adjunct 
rehabilitation is vital to achieving enhanced functional recovery. Anti-Nogo-A therapy has a broad 
therapeutic window. Efficacy has been demonstrated when administration takes place 
immediately169 after stroke, and at various time points up to nine weeks post-stroke162,164. This 
suggests the potential to extend the limited therapeutic window for stroke.  
The addition of a rehabilitation schedule to treatment involving anti-Nogo-A therapy has been 
shown to improve recovery beyond either treatment alone165. However, this effect was only 
produced when rehabilitation was provided after anti-Nogo-A therapy. Following a photothrombotic 
infarction, rats that received anti-Nogo-A therapy followed two weeks later by intensive task-specific 
forepaw training performed better than those without rehabilitation or those undergoing 
rehabilitation concurrently with treatment. Furthermore, the group of rats that received concurrent 
rehabilitation and treatment performed worse than animals receiving no treatment. On histology, 
the authors reported that rats in both treatment schedules showed enhanced axon growth, but the 
rats in the simultaneous treatment schedule showed an increase in aberrant branching and 
overgrowth of axons beyond the grey/white matter boundary. Similar results have been seen in the 
treatment of experimental spinal cord injury with anti-Nogo-A therapy173. This suggests that anti-
Nogo-A treatment causes disinhibition of neuroplasticity, which in the context of specific and 
intentional rehabilitation leads to functional reorganisation of neuronal networks, but in the absence 
of rehabilitation results in detrimental, disorganised restructuring. This is an important concept that 
should be considered in the design of clinical trials of anti-Nogo-A treatment for ischaemic stroke. 
The remarkable improvements seen in the anti-Nogo treatment of CNS lesions in animal models 
have not yet been translated into human therapy. Phase I clinical trials have demonstrated the 
safety of anti-Nogo-A monoclonal antibodies in the treatment of SCI and amyotrophic lateral 
sclerosis(ALS)174. Following the determination that intrathecal delivery of the anti-Nogo-A 
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monoclonal antibody ATI-355 is safe in humans, a phase II trial with a placebo control is currently 
being planned by the Schwab group. A phase II clinical trial of ozanezumab, another anti-Nogo-A 
monoclonal antibody, failed to demonstrate efficacy for ALS, suggesting that the Nogo system is not 
a therapeutic target for this disease175. There are currently no clinical trials for anti-Nogo-A therapy 
in stroke. 
 
1.4: Stem Cells 
Stem cells are multipotent or pluripotent populations of undifferentiated cells that have the capacity 
to regenerate themselves and to differentiate into mature cell types in response to environmental 
cues176. In development, blastocysts divide into three main embryonic lineages that eventually give 
rise to all adult tissues; the ectoderm, mesoderm and endoderm. In addition to adult somatic cells, 
embryonic stem cells also give rise to specialised populations of adult stem cells, which serve a 
maintenance function in replacing aged and damaged tissues. As a result, there are many 
populations of multipotent adult progenitor cell, which can be distinguished by their differentiation 
potential. Mesenchymal stem cells reside in niches throughout the body and can give rise to many 
tissue types including bone, muscle, adipose, neurons and glia177. Haematopoietic stem cells reside 
in bone marrow and differentiate into the cellular components of blood178. Neural stem cells, which 
can give rise to neurons, astrocytes and oligodendrocytes are more limited and can be found mainly 
within two regions – the subventricular zone and the subgranular zone179. Other examples include 
intestinal mucosal stem cells, epithelial stem cells, endothelial stem cells and dental pulp stem cells 
(DPSC). Most organs have a stem cell population maintaining them. 
Stem cells can also be derived artificially from somatic cells. The novel induction of stem cell 
properties in adult somatic cells was first described in the landmark study by Okita et.al. (2007)180. 
This study demonstrated that fibroblasts could be transformed into highly proliferative, pluripotent 
cells through retroviral transduction with embryonic transcription factors (oct 3|4, sox-2, c-myc and 
klf-4). Induced pluripotent stem cells (iPSC) are antigenically compatible with the donor and are 






1.4.1: Cell-Based Therapy 
The ability of stem cells to proliferate and repopulate damaged tissues lead to the paradigm of cell-
based therapy. This field has its origins in the transplantation of haematopoietic stem cells by E.D. 
Thomas in the 1950’s181,182. Transplantation of allogeneic haematopoietic stem cells from bone 
marrow is now routinely carried out to replace cells following full-body irradiation for leukaemia. 
Cell-based therapy has since been investigated as a potential treatment option in a number of 
neurological conditions that result from tissue loss, including traumatic brain injury, spinal cord 
injury and degenerative diseases such as Alzheimer’s and Parkinson’s.  
Cell-based therapy has also been extensively investigated as a potential treatment option for 
ischaemic stroke. The application of cell-based therapy has been tested in numerous pre-clinical 
stroke studies183,184. Significant improvement in cognitive and sensorimotor function has been 
demonstrated in animal stroke models through performance in tasks specific to the neurological 
damage caused. Efficacy has been demonstrated following administration of several types of stem 
cell, including mesenchymal stem cells (MSC)185, haematopoietic stem cells186, iPSC187,188 and DPSC189 
among others. While these results are promising, several issues still need to be considered with 
regards to optimising cell-based therapy for ischaemic stroke. These include factors relating to the 
type of stem cell used, the source, the administration route, the timing of transplantation and 
combination with other interventions, such as rehabilitation.  
The optimism gained from these animal studies should be tempered with caution, a lesson learned 
in the field of cell-based therapy for Parkinson’s disease. Following the success of foetal ventral 
mesencephalic neuron transplantation in animal models of Parkinson’s disease190,191, a small phase 1 
clinical trial was conducted and several of the subjects experienced significant improvement in their 
Parkinson’s symptoms192. This led to two larger double-blind placebo controlled clinical trials. In an 
outcome reminiscent of the failed translation of neuroprotective therapies, the results from both of 
these trials indicated that foetal ventral mesencephalic stem cell transplantation was not efficacious 
for Parkinson’s disease in humans. Moreover, the treatment was associated with significant adverse 
events193,194. Therefore, success in preclinical studies of stem cell therapy in stroke does not 
guarantee success in translation. 
Cells used in therapy may be pluripotent, such as embryonic stem cells and iPSC, or multipotent 
progenitor cells. While the rapid proliferation and unlimited differentiation potential of pluripotent 
cells may seem ideal, these same properties lead to an increased risk of tumorigenicity. The high 
proliferation rate, myc expression195 and telomerase activity196 of embryonic stem cells causes 
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genomic instability197,198. As a result, transplantation of embryonic stem cells into animal models 
characteristically results in teratoma formation199,200 and may result in malignancy201. The use of iPSC 
likewise results in an increased risk of tumour formation. Other than a rapid proliferation rate, iPSCs 
also necessarily overexpress the oncogene c-Myc180, sustain mutagenesis during viral 
transduction202,203 and retain accumulated genomic damage from their existence as somatic cells204. 
While there are no reported cases of tumour formation in humans following pluripotent stem cell 
transplantation, at least one person has developed brain tumours derived from transplanted foetal 
neural stem cells196. Conversely, adult multipotent stem cells carry a lower risk205. The other 
advantage to these is that they can be derived from an autologous source, which eliminates the risk 
of immune reactivity. Adult multipotent stem cells have been transplanted into humans in numerous 
studies without cell-related adverse events206–222. Therefore, these are a more appropriate cell type 
for therapeutic use. 
Another option is to transplant with pre-differentiated neurons produced ex-vivo. One advantage to 
this method is that these cells are post-mitotic and are therefore have negligible risk of tumour 
formation. The other advantage is that the neuronal fate of transplanted cells is guaranteed, as 
opposed to stem cell transplantations lead predominantly to astrocytic differentiation189,223–225, 
which may reduce efficacy. One study demonstrated 30% transplant cell survival and greatly 
enhanced functional outcomes following transplantation of pre-differentiated GABAergic neurons225. 
The authors suggest this may be due to the regulatory role of GABA in neuroplasticity. 
Donor age may also impact the efficacy of cell-based therapy. While stem cells are present 
throughout life, extensive proliferation and accumulated damage effects their stem-like properties. 
For example, the differentiation potential of mesenchymal stem cells sourced from adipose226 and 
bone marrow227 is reduced in advancing age, with fewer cells able to differentiate into mature 
chondrocytes or osteoblasts. This inability of aged mesenchymal stem cells to adequately replace 
osteoblast populations has been hypothesised as a reason for the reduction of bone mineral density 
with advancing age228. Furthermore, the in vitro proliferation rate of mesenchymal stem cells 
decreases with donor age227,229. This has implications for cell-based therapy as autologous therapy 
requires in vitro expansion prior to implantation, and slowed proliferation may result in delayed 
treatment. As a result, cells sourced from younger donors may provide superior outcomes. One 
recent pre-clinical study has demonstrated that a rat stroke model treated with human 
mesenchymal stem cells from younger donors achieved superior functional outcomes in behaviour 
testing than when treated with cells from older donors185.  
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Delivery of cells to the site of action has been achieved by direct intracerebral transplantation and 
via intravascular routes. Intracerebral transplantation ensures that cells are delivered directly to the 
brain, giving them the greatest chance of exhibiting an effect. However, this route is highly invasive 
and carries a high risk of serious adverse events230,231. Furthermore, the migratory potential of cells 
transplanted directly into the brain is limited by glial scar formation225, a limitation that presumably 
would not be shared by intravascular transplantation. Stem cells migrate towards the chemokine 
SDF-1, which is highly expressed in the post-stroke brain. In addition to this, stem cells transplanted 
via an intravascular route can transmigrate the blood-brain barrier232–234. Therefore, administration 
of stem cells through an intravascular route results in engraftment at the site of action and causes 
enhanced functional recovery232. A recent study has suggested that an intravenous route may be 
superior to an intra-arterial route, as intra-arterial administration resulted in increased inflammatory 
damage and poorer outcomes in functional behaviour testing186. 
One of the advantages of cell-based therapy is that it promises to extend the treatment window for 
stroke. Pre-clinical trials have shown efficacy when treatment is provided up to two weeks235 after 
the ischaemic event, though a systematic review has determined that early administration results in 
greater efficacy183. A study using a mouse model of ischaemic stroke determined that the greatest 
engraftment rates were achieved from intra-arterial transplantation at three days235. While it is 
unclear how this would translate to human studies, it is noteworthy that cells transplanted at two 
earlier timepoints had poorer engraftment rates. This suggests that factors relating to the evolution 
of ischaemic stroke influence transplanted cells, and this will need to be addressed to optimise cell-
based stroke therapy in humans. The authors suggest that this relates to increased VCAM-1 
expression, though this was also upregulated at earlier time points. Other possible explanations for 
this effect are that acute inflammation at earlier timepoints is damaging to transplanted cells, that 
blood-brain barrier permeability is maximised at day three236(discussed further in section 1.5) and 
that peri-infarct expression of the chemokine SDF-1 also peaks at day three183. 
There is also evidence that like anti-Nogo and PNN-targeted therapy, the combination of stem cell 
transplantation and rehabilitation is synergistic, or at least additive237. The optimum timing schedule 
for stem cell and rehabilitation combination therapy has not been investigated to date. Given that 
cell-based therapy may act in part by stimulating neuroplasticity (discussed in section 1.4.4), it is 
likely that it also requires guidance through Hebbian mechanisms to achieve maximum efficacy. 
At least 23 early-phase clinical trials of cell-based therapy for ischaemic stroke have been conducted 
so far, with a combined sample size of 672 patients206–222,230,231,238–241. Of these, nine included control 
groups and the rest were either phase I or pilot studies. The majority (16) used cells from an 
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autologous source, including MSC derived from bone marrow, haematopoietic stem cells and 
peripheral blood stem cells. Cells derived from exogenous sources included fetal stem cells, neuronal 
stem cells, multipotent progenitor cells and modified mesenchymal stem cells. One early study 
attempted to use cells derived from porcine foetus, though this was aborted after serious adverse 
events were reported238. Transplantation routes used in these experiments included intracerebral 
(8), subarachnoid (1) intravenous (9) and intra-arterial (5), with one study testing both intravenous 
and intra-arterial. The main outcome from these studies was that cell-based therapy was generally 
safe and well-tolerated, with the majority of adverse events being related to the transplantation 
procedure and not the cells. Despite the many clinical trials that have been published, the positive 
results seen in preclinical studies have not been replicated unequivocally in human clinical trials. 
Some of the possible reasons for this are that human stroke is more heterogeneous than animal 
stroke models, that measuring functional outcomes in humans is more complex than standardised 
behaviour testing in animals, and that the majority of these studies had small sample sizes without 
control groups. A recent systematic review suggested that there is a need for a phase 3 clinical trial 
to determine whether cell-based therapy for ischaemic stroke is efficacious in humans, as this is 
difficult to infer from phase 2 trials only242. 
 
1.4.2: Dental Pulp Stem Cells 
First described by Gronthos et.al. (2000), DPSC are a heterogeneous population of highly 
proliferative, multipotent cells residing in perivascular niches within adult teeth 243. DPSC are similar 
to MSC in terms of their differentiation potential and are thought to be of a neuroectodermal origin 
and a subpopulation of DPSC have been shown to derive from Schwann cells during development244. 
The most likely functions of adult DPSC are to repair nerve and vascular tissue and to replenish 
odontoblast populations for maintenance of dentine in teeth. DPSC seem to be present throughout 
life as long as dental pulp remains intact245. 
DPSC have been studied extensively both in vivo and in vitro, and have been shown to be rapidly 
expandable and multipotent. Aside from their odontoblastic potential, DPSC have been 
demonstrated to differentiate into neurons, adipocytes, myocytes, chondrocytes246,247 and retinal 
photoreceptor-like cells248. Under the appropriate conditions, DPSC are capable of forming 
neurospheres, which contain cells expressing various neuronal and glial antigens249. Furthermore, 
neurons produced through differentiation of DPSC are functionally active, with detectable action 
potentials and ion channels246.  
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Molecular characterisation of undifferentiated DPSC has revealed that they express surface antigens 
and other markers also associated with other types of stem cell. Cluster of differentiation (CD) 
markers and others can be used to identify populations of multipotent stem cells177. As DPSC are a 
heterogeneous population, no single set of markers has been identified to distinguish DPSC from 
other stem cell types. Furthermore, different subpopulations of DPSC with distinct stem-like 
characteristics have been shown to express different surface antigens250. In general, DPSC have been 
shown to express the mesenchymal stem cell markers CD105, CD73, CD90, CD44 and STRO-1, and to 
not express the negative MSC selection markers CD45, CD34, CD14 or HLA-DR248,251–253. DPSC have 
also been shown to express the stem cell transcription factors OCT-4 and NANOG254–256. The 
significance of this is that the expression profile of DPSC demonstrates that they are phenotypically 
similar to other adult multipotent cell types. This is also experimentally relevant as it means that 
DPSC and sub-populations can be isolated from primary cultures using techniques such as magnetic- 
and fluorescence-activated cell-sorting. 
DPSC express cytokines and receptor molecules that may render them useful in cell-based therapies. 
Molecular studies have determined that DPSC express the growth factors insulin-like growth factor-
1, insulin-like growth factor-binding protein-6 and vascular endothelial growth factor234, the 
immunomodulatory cytokines interleukin-10, tumour necrosis factor (TNF)-α and TNF-β257 and the 
chemotactic factor stromal-derived factor-1 (SDF-1)258. Furthermore, DPSC express chemokine 
receptor CXCR4, thus enabling them to migrate along SDF-1 concentration gradients259. These 
characteristics relate to the hypothetical mechanisms of action of cell-based therapy, which are 
discussed further in section 1.4.3. 
Their multipotentiality, clinical accessibility, presence in older patients and in vitro expandability 
make DPSC a promising candidate source for cell-based therapy. DPSC, like other adult stem cells, 
also have an advantage over pluripotent stem cells such as iPSC or those derived from embryos in 
that they are less likely to be tumorigenic. Specifically, immortalised DPSC do not form tumours 
when transplanted into immunocompromised animals260. As a result, DPSC have been investigated in 
pre-clinical studies as a therapeutic option for a broad range of disorders including bone 
defects261,262, liver cirrhosis263 and Parkinson’s disease264.  
Of relevance to this review, DPSC have also been investigated as a treatment option to enhance 
recovery following ischaemic stroke. Direct intracerebral transplantation of human DPSC in a rat 
model of ischaemic stroke resulted significant enhancement in performance of behaviour tests. This 
effect was underpinned by a low survival rate of transplanted cells, but surviving cells migrated 
towards the ischaemic border zone and differentiated predominantly towards a glial phenotype189. 
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Administration of a DPSC side population in a rat stroke model265 and administration of DPSC from 
human deciduous teeth in a mouse model of neonatal hypoxia ischaemia266 have shown similar 
results. Interestingly, administration of DPSC conditioned media alone was sufficient to significantly 
enhance recovery through stimulation of endogenous neuroplasticity267 and neuroprotection266. The 
effect of a one-time dose of conditioned medium is presumably attenuated as compared with cell 
transplantation, which would provide prolonged administration of the active components. 
Transplanted cells survive at least four weeks in the host brain189,225, though it is likely that they 
survive much longer. This suggests that at least part of the efficacy of DPSC therapy in stroke is due 
to soluble factors expressed by the cells. A recent study has reproduced the results showing 
enhancement of recovery in a rat model of focal infarct and also demonstrated that DPSC were more 
efficacious than marrow-derived MSC268. Therefore, DPSC are a promising cell type that should 
continue to be investigated as an option for cell-based therapy in ischaemic stroke.  
 
1.4.3: Mechanism of Action 
The mechanism of action of cell-based stroke therapy was originally thought to be replacement of 
lost tissue by neural differentiation and integration into surviving circuits. However, the low 
engraftment rates of transplanted stem cells and the even lower rates of neuronal differentiation 
suggest that other mechanisms are likely189,269. The predominant model is the bystander effect, 
which suggests that transplanted stem cells stimulate endogenous repair machinery through 
paracrine signalling269. The specific mechanisms involved in the bystander effect include 
neuroprotection, immunomodulation, angiogenesis, biobridge formation and neuroplasticity270,271, 
which is the main concept explored in this review. 
Neuroplasticity occurs through neuroanatomical and electrophysiological changes including 
axonogenesis, dendritic arborisation and long-term potentiation (discussed in section 1.2). There is 
compelling evidence from animal studies that transplantation of stem cells enhances these aspects 
of neuroplasticity. An example of this is from Arthur et.al.258, who demonstrated that injection of 
human DPSC into chick embryos resulted in aberrant branching of peripheral nerve axons, 
suggesting that they exerted an effect through axonal guidance. In another study, a rat stroke model 
demonstrated enhanced branching of cortical dendrites and increased midline-crossing axons 
following engraftment with human neural stem cells272. This neuroanatomic reorganisation was 
correlated with significant improvement in behaviour test performance. A similar effect was shown 
in a rat model of neonatal hypoxia-ischaemia, wherein human neural stem cell engraftment caused 
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significant ipsilesional axonal branching and improved functional outcomes273. Finally, cell-based 
therapy can also enhance the electrophysiological substrate of neuroplasticity. Transplantation of 
human MSC into mice following hippocampal insult partially restored hippocampal long-term 
potentiation and synaptic transmission as measured by brain slice microelectrode array274. This 
effect was also correlated with improved performance in maze tests, which implied an enhancement 
of spatial memory. Thus, cell-based therapy has been shown to enhance three primary components 
of neuroplasticity: axonogenesis, dendritic arborisation and long-term potentiation. 
The hypothesis that cell-based therapy enhances performance in behaviour tests through 
neuroplasticity should be self-evident, as any change behaviour is necessarily precipitated by 
underlying neuroanatomical reorganisation. A more important question is how cell-based therapy 
stimulates neuroplasticity. The hypothetical mechanism through which stem cells enhance 
neuroplasticity includes the expression of neurotrophic factors. For example, MSC secrete brain-
derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and nerve growth 
factor (NGF)275–277. BDNF stimulates branching of axon terminals and promotes the differentiation 
and maturation of endogenous neural stem cells278,279. NGF causes axonal branching and dendritic 
arborisation, while expression of glial-derived neurotrophic factor (GDNF) causes axonal 
extension280. Furthermore, over-expression of BDNF and GDNF in MSC increases their efficacy in 
rodent stroke models281,282. 
 More direct evidence for the role of cytokines in stem cell-induced neuroplasticity is found through 
knock-down or receptor inhibition studies. Antagonism of the SDF-1 receptor CXCR-4 inhibits the 
axon-guidance effect of DPSC on peripheral nerves258. Likewise, transgenic neural stem cells 
deficient in BDNF were shown through behaviour testing to have an attenuated efficacy in a rat 
model of traumatic brain injury283 and vascular endothelial growth factor (VEGF) inhibition was 
shown to prevent dendrite branching and enhancement of axon transport by NSC272. Both 
neuroplasticity and the interactions that occur in cell-based therapy are highly complex. Thus, it is 
likely that these cytokines represent a number of redundant systems through which cell-based 




1.5: The Blood-Brain Barrier 
As the gatekeeper to the brain parenchyma, the blood-brain barrier (BBB) plays a significant role in 
the development of new stroke therapies. Firstly, the BBB is affected by ischaemic stroke and its 
activity underlies the processes of damage and repair. Secondly, any treatment administered by an 
intravascular route must be able to cross the BBB to gain access to the CNS. The remainder of this 
review will address these concepts.  
The BBB refers to the specialised structure of the neurovascular unit. Anatomically, the BBB is 
composed of a layer of endothelial cells surrounded by basement membrane, pericytes and 
astrocyte processes (Figure 5). Unlike other capillaries, the endothelial layer of the BBB is continuous 
and joined by tight junctions284,285. The main function of the BBB is to segregate the environment of 
the brain parenchyma from peripheral circulation. The extracellular environment of the CNS needs 
to maintain a balance of ions and neurotransmitters to maintain normal neuronal function. Without 
the BBB, the CNS would be contaminated by humoral analogues of neurotransmitters, which 
perform different functions in the periphery. In general, the BBB is selectively impermeable to large, 
polar molecules286. Various sources estimate the maximum size for passive diffusion across the BBB 
to range from 180 Da287 to 800 Da288. However, the BBB is not a passive filter. It actively transports 
substances between circulation and the CNS parenchyma through transcytosis289. In addition, 
passage across the BBB may be facilitated by a global increase in permeability between BBB 




Figure 5: A diagram of the cellular and molecular structure of the blood-brain barrier. Characteristic 
features include the close association between endothelial cells, pericytes and astrocytes, presence of 
tight junctions and transcytotic vesicles. Tight junctions anchor to cytoskeletal components and join 
the edges of adjacent endothelial cells. 
 
1.5.1: Structure and Function 
One of the defining features of the BBB is the presence of tight junctions at the interface between 
adjacent endothelial cells. Microscopically, tight junctions appear as focally fused segments of 
endothelial cell membranes occurring in regions of overlap. At a molecular level, the tight junction 
complex consists of the cytoplasmic protein zonula occludens (ZO)-1, which binds to ZO2, ZO3 and 
cytoskeletal actin filaments. The transmembrane proteins occludin and claudin are anchored to ZO1, 
while their transmembrane domains bind to their counterparts on adjacent endothelial cells287 
(Figure 5). Imaging of these proteins in brain endothelial sections reveals a characteristic honeycomb 
appearance. Interestingly, when brain microvascular endothelial cells have been cultured in vitro, 
occludin relocalised to the cytoplasm, whereas claudin remained at the cell membrane291,292.  
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An important cellular component of the BBB is the pericyte, which provides structural support for 
the endothelium as well as playing a role in regulating perfusion. Pericytes contain contractile 
elements in a similar arrangement to smooth muscle tissue293,294, which relates to two important 
functions: 1) Pericytes relax to dilate capillaries in response to neuronal stimulation and 2) Pericytes 
contract to restrict flow in ischaemia.  
Due to the close association between astrocyte processes and brain microvascular endothelial cells, 
it has long been hypothesised that astrocytes are involved in the induction of BBB characteristics in 
endothelial cells295,296. It has been demonstrated in vitro that co-culture with astrocytes induces BBB 
morphology in endothelial cells, including the expression of the tight junction proteins occludin and 
claudin297. Furthermore, endothelial monolayers exposed to astrocytes present a measurable 
increase in transcellular resistance298. This effect has also been produced by exposing endothelial cell 
cultures to astrocyte conditioned media299. Thus, the induction of a BBB phenotype in endothelial 
cells is likely to be the result of a soluble factor produced by astrocytes. Some candidate factors 
include glial-derived neurotrophic factor, basic fibroblast growth factor and angiopoietin300. 
Numerous studies have employed in vitro models for studying BBB permeability with regards to 
substances of interest301–303. Early models used a monolayer of brain microvascular endothelial cells 
adhered to a porous substrate, however it was found that endothelial cells lost their tight junctions 
when outside of the brain302. Due to the astrocyte induction hypothesis, subsequent models have 
used a bilayered co-culture of astrocytes and endothelial cells. Electron microscopy of these more 
complete BBB models has shown that astrocyte processes extend through the porous substrate to 
contact endothelial cells302. This resembles the structure of the BBB in vivo. 
 
1.5.2: Response to Infarction 
Increased BBB permeability occurs following most types of CNS injury and is usually associated with 
oedema. Following ischaemic stroke, there is a well-characterised biphasic increase in BBB 
permeability304,305. This activity is the result of two separate processes involving the BBB. The initial 
peak of permeability is a result of ischaemic damage, while the second peak is the result of repair 
processes236. 
The first peak in BBB permeability occurs at approximately 24 hours post-infarct and is the direct 
result of ischaemic damage to cerebral blood vessels as well as an endothelial response to 
inflammation. Inflammatory states are thought to increase BBB permeability through changes in 
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tight junction regulation. Exposure to the proinflammatory cytokines interferon γ, interleukin 1b and 
tumour necrosis factor α has been shown to cause tight junction dysregulation in an in vitro 
model306. Furthermore, ZO3 expression has been shown to become disordered in response to 
inflammation associated with autoimmune encephalitis307.  
The second wave of BBB permeability, which occurs approximately 72 hours after infarction, is 
associated with angiogenesis. The oedema that characterises the initial peak in permeability is 
generally absent during the second peak. This time point is also characterised by an upregulation of 
members of the vascular endothelial growth factor family, which act both to stimulate angiogenesis 
and to increase BBB permeability236. An important early study by Zhang et.al. used a rodent stroke 
model to demonstrate that administration of VEGFa one hour post-infarct increased oedema and 
tissue damage, whereas administration at 48 hours post-infarct improved functional outcomes and 
was not associated with oedema308. This supports the hypothesis that the second wave of BBB 
permeability is not related to oedema or further tissue damage. 
A recent MRI study in humans has challenged the current paradigm of biphasic BBB regulation in 
ischaemic stroke309. This study recruited 42 patients and used dynamic contrast-enhanced MRI to 
measure BBB permeability within the infarct and the contralateral homotopic region. It was found 
that BBB permeability was elevated at all time points up to 90 hours post-stroke. However, this was 
not a longitudinal study as each patient was imaged at a single time point and so continuous data 
were not available. Furthermore, baseline BBB permeability was obtained by imaging the 
contralateral hemisphere, which assumes that infarct doesn’t affect BBB integrity in distant brain 
regions. 
 
1.5.3: Implications for Cell-Based Therapy 
The BBB represents a potential barrier to intravascular cell-based stroke therapy, as any treatment 
product introduced into the vascular compartment must cross the BBB to access its therapeutic 
target. This issue has been tackled extensively in the development of centrally-acting 
pharmaceuticals. Several previous studies have demonstrated that MSC transplanted intravascularly 
can enter the brain parenchyma from circulation, however the mechanism underlying that effect has 
not been well-characterised209,232,233,310. One aspect that will influence this is the increase in BBB 
permeability that occurs after stroke. This may be one of the underlying reasons that early post-
stroke transplantation has resulted in superior outcomes in animal studies of cell-based therapy. 
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However, stem cells have been shown to migrate from circulation into the brain even when 
transplanted at much later time points when the BBB is no longer as permeable235,311. Therefore, it is 
likely that stem cells mediate entry to the brain parenchyma through their interactions with the 
cerebral endothelium. 
In a study by Rosenblum et.al.235, MSC were transplanted into mice via an intra-arterial injection at 
various time points from six hours to 14 days after a hypoxia-ischaemia model of stroke. The results 
demonstrated that while MSC crossed the BBB at all time points, maximum engraftment occurred 
following transplantation at day three. The authors hypothesised that this related to an increase in 
diapedesis through expression of vascular cell adhesion molecule-1 (VCAM-1). However, VCAM-1 
was shown to also be strongly upregulated at all time points. Therefore, an alternative hypothesis is 
that transplantation three days post-stroke resulted in maximum engraftment due to coincident 
endogenous enhancement of BBB permeability. 
While intravascular delivery of cell-based therapy for stroke has demonstrated efficacy in pre-clinical 
studies and stem cells have been shown to cross the BBB, the mechanisms underlying this have not 
been fully elucidated. Characterisation of this mechanism could inform the optimisation of cell-




1.6: Aims and Rationale 
The chronic cognitive and sensory-motor disability caused by ischaemic stroke brings vast economic, 
social and personal costs. Current stroke management can only limit the damage caused by stroke. 
Due to the limited therapeutic window of recanalization, only a small proportion of patients are 
treated. There is a need for treatment options that are available to more patients and that can 
restore lost function after stroke, rather than only limiting damage. One promising treatment 
modality is cell-based therapy.  
Stem cell transplantation following stroke results in improved performance in behaviour testing. This 
effect is thought to occur due to paracrine signalling rather than tissue replacement. Crucially, 
transplantation through both direct and intravascular routes has been shown to be efficacious. This 
is important because intracerebral transplantation is invasive and is more likely to result in adverse 
events than intravascular transplantation. Transplanted stem cells have been shown to migrate from 
circulation to the site of injury. The mechanism by which transplanted stem cells are able to migrate 
across the blood-brain barrier (BBB) is unclear. One hypothesis is that stem cells enhance BBB 
permeability through the paracrine secretion of VEGF-a. Understanding this mechanism will help to 
design and optimise cell-based therapy for stroke, as stem cell populations more capable of 
migrating to the site of injury could be selected.  
While many pre-clinical studies have demonstrated the efficacy of stem cell transplantation in 
stroke, the mechanism of action has not yet been fully elucidated. One hypothesis is that 
transplanted stem cells interrupt endogenous systems responsible for the inhibition of 
neuroplasticity. Degradation of PNNs is a likely candidate as PNNs are responsible for inhibition of 
neuroplasticity in adult mammals. Furthermore, removal of PNNs results in a window of increased 
neuroplasticity. However, previous studies have demonstrated that PNNs are modified 








To test these hypotheses, the aims of this thesis are as follows: 
  
1. To test the ability of DPSC to enhance blood-brain barrier permeability and to investigate the 
mechanism by which this occurs. 
2. To investigate the ability of DPSC to alter the expression of PNNs and to identify the 
expression of enzymes that may be responsible for this effect. 
3. To characterise spatial and temporal changes in the distribution of major PNN components 
following stroke. 
4. To develop a standardised model of chronic stroke for the assessment of potential stroke 
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Chapter 2 Supplementary Discussion 
 
Following publication of this chapter, several points remain to be explored regarding both technical 
aspects of the study and the clinical implications of its outcomes. Firstly, whilst one of the outcomes 
of this study was to validate the use of a cross-species co-culture model of the BBB, this facet 
deserves more explanation. The main conclusion of this paper is that human DPSC can increase 
permeability across the BBB through a VEGF-dependent mechanism and it was hypothesised that 
this mechanism would allow DPSC to transmigrate the BBB. One question this raises is whether this 
VEGF-dependent mechanism manifests as an increase in permeability of existing vessels or as the 
creation of new cerebral vessels, which are inherently permeable. Whichever mechanism is 
responsible, it also remains to be discussed that an increase in BBB permeability may also enable the 
passage of other blood products into the brain parenchyma, which may result in adverse events. 
Co-cultures of astrocyte and endothelial cell monolayers are a well-characterised in vitro BBB model. 
This study developed a model using a co-culture of murine astrocytes and human endothelial cells. 
The main reason for this is that while human endothelial cells are readily accessible, human 
astrocytes are much more ethically burdensome and difficult to obtain. The BBB is a highly 
conserved feature1 and has a similar structure among mammals2. We hypothesised that the 
signalling mechanisms responsible for astrocyte-induced BBB properties in endothelial cells would 
be similar enough between the two species to allow for sufficient cross-reactivity. While at the time 
of writing the responsible astrocytic factor has not been determined, we attempted to validate this 
model empirically. Namely, the co-culture of murine astrocytes with human endothelial cells 
resulted in an increase in occludin staining (Figure 2). Furthermore, this model was demonstrated to 
have similar permeability properties to the BBB (Figure 3). Together, these results provide evidence 
in support of the validity of this cross-species BBB model. 
VEGF-a has been shown to increase vessel permeability, but also to stimulate the formation of new 
vessels. In particular, post-stroke endogenous upregulation of VEGF-a and its receptors is associated 
with a wave of angiogenesis. These new vessels are more permeable than mature vessels. It is 
possible that rather than increasing permeability in mature vessels, the VEGF-dependent increase in 
BBB permeability occurs as a by-product of new vessel formation. It would be possible to address 
this hypothesis by introducing a condition where endothelial proliferation is inhibited but the other 
downstream effects of VEGF-a are maintained. For example, raf-1 inhibition would prevent cell cycle 
stimulation downstream of PCK, while not interacting with the effects of VEGF-a downstream of 
PI3K. Care must be taken designing such an experiment as at least one raf-1 inhibitor, Sorafenib, also 
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directly blocks VEGFR23. Another hypothesis is that increased permeability in mature vessels is part 
of the process of angiogenesis that the two possible mechanisms described are components of one 
single mechanism. Even if DPSC-induced BBB permeability is the result of permeable immature 
vessels, the outcome of increased BBB permeability remains the same. 
The interaction between the peripheral immune system and the brain is highly regulated and was 
once thought to be completely separate as per the concept of immune privilege. The BBB is largely 
responsible for limiting access of peripheral immune system components to the brain. If DPSC can 
transmigrate the BBB by increasing permeability, then this may also allow infiltration of peripheral 
immune cells. Whether this occurs depends on the duration and extent of BBB ‘opening’. If BBB 
permeability only increases while in close proximity to transplanted DPSC, then extensive infiltration 
of other cells is unlikely. However, if DPSC transplantation triggers an extended period of global BBB 
permeability, then leukocyte infiltration is more likely. This could be determined in vivo by 
measuring the numbers of both DPSC and peripheral immune cells in the brain following 
intravascular DPSC transplantation. The clinical implication of this are not clear, though neural 
damage caused by extended exposure to cytotoxic products of immune cells has been linked to 
several neurodegenerative processes including Alzheimer’s disease, Parkinson’s disease and multiple 
sclerosis4. However, peripheral immune cells already gain access to the brain following stroke5 and 
so it is not clear whether any increase in this caused by DPSC transplantation would significantly 
increase the probability of adverse events. The possibility of exacerbating neural damage by cell-
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Background: Human dental pulp stem cells (DPSC) are a promising candidate for cell-based therapy 
following brain injury. DPSC have previously been shown to express the cytokines stromal-derived factor 1 
(SDF-1) and vascular endothelial growth factor (VEGF), as well as chemokine receptor type-4 (CXCR4), 
which allow DPSC to migrate to areas of damage when transplanted into the brain. DPSC also need to 
express enzymes to facilitate their migration through tissues. Some of the major candidates are members 
of the enzyme families matrix metalloproteinase (MMP) and a-disintegrin and metalloprotease with 
thrombospondin motifs (ADAMTS). MMPs and ADAMTSs are capable of degrading the perineuronal net 
(PNN), a structure important in the control of adult neuroplasticity. To date, the enzymatic profile of DPSC 
has not yet been fully characterised. The present study aimed to assess the expression of MMPs and 
ADAMTSs by DPSC and to confirm the biological activity of the expressed enzymes in three in vitro settings.  
 
Methods: Enzyme expression was assessed by western blot of DPSC conditioned media. Enzymatic activity 
was assessed by substrate digestion analysis, gel zymography, in vitro brain slice digestion and live-cell 
digestion assays.  
 
Results: We found DPSC express MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-13, ADAMTS-4 and 
ADAMTS-5. DPSC conditioned media was capable of digesting aggrecan, one of the key PNN components. 
MMP-2 was confirmed to be active by gel-zymography of immunoprecipitated conditioned media samples.  
 
Conclusions: Adult human DPSC express active enzymes capable of degrading PNNs, which may contribute 












Within perivascular niches of adult human teeth reside populations of highly proliferative and multipotent 
cells of neural crest origin termed dental pulp stem cells (DPSC), first described by Gronthos et al. (2000)1. 
We have shown that DPSC populations are present throughout life and maintain their differentiation 
potential even when isolated from older teeth (unpublished data) These properties, in conjunction with 
their clinical accessibility and the possibility of auto-transplantation, have made DPSC a promising 
candidate for cell-based therapy in the field of brain repair. 
 The initial hypothesis for the mechanism of cell-based therapy was that stem cells transplanted into 
the damaged brain would replace lost tissue. Several studies have demonstrated the efficacy of DPSC 
transplantation in animal models of CNS injury2,3. In particular, we have observed that following 
intracerebral transplantation, DPSC will migrate to the ischaemic border zone of an experimental stroke in 
rats, resulting in significant improvement in functional outcomes4. However, only a small population of 
transplanted cells engraft in the host brain. One of the unsolved puzzles from these investigations is how 
these small populations contribute to the level of recovery observed. 
 The current predominant hypothesis is that DPSC enhance functional recovery through the 
paracrine secretion of soluble products that support endogenous recovery processes. This bystander effect 
has been attributed to the stimulation of neuroplasticity, angiogenesis, neuroprotection and 
immunomodulation5. 
 We have previously demonstrated that DPSC express VEGFa and SDF-1 at biologically relevant 
quantities that may influence the way they interact with brain microvascular tissue and migrate to the site 
of damage6,7. 
 Given the ability of DPSC to migrate through the brain parenchyma, it is likely that they would 
express enzymes capable of degrading the extracellular matrix (ECM) of the brain. One of the key types of 
ECM component in the brain are the chondroitin sulfate proteoglycans, which are present in the general 
brain ECM and also assemble into structures called perineuronal nets (PNNs). The PNNs are specialised 
aggregations of ECM on the surface of sub-populations of neurons, which have been implicated in 
controlling neural plasticity8. The PNNs are distributed as mesh-like structures surrounding primarily 
inhibitory interneurons of the motor and sensory cortices, the hippocampus and Purkinje neurons of the 
cerebellar cortex9. The molecular structure of the PNNs and the enzymes responsible for their degradation 
are outlined in figure 1. 
 Enzymes capable of degrading PNNs include members of the MMP, ADAMTS and hyaluronidase 
families (figure 1). Healthy dental pulp has been shown to express MMP-1, -2, -13, and -14 at both the RNA 
and protein level and to produce active MMP-910,11 DPSC specifically have been shown to express MMP-1 
and MMP-20 during osteogenic differentiation at the levels of RNA and protein synthesis12,13. The presence 




context of cell-based therapy and enhancement of plasticity. 
 This study aimed to characterise the expression and activity of enzymes capable of degrading the 
PNN, which may contribute to the observed functional benefits of DPSC transplantation. These data will 
contribute towards building a more complete enzymatic profile of DPSC, which may have implications for 









DPSC  (H1-H6) were isolated from healthy donors aged 15-25 years following routine tooth extraction, with 
human ethics approval from The University of Adelaide. DPSC were cultured in α-modified Eagle's Medium 
(Sigma, M4526) containing 10mL/L fetal calf serum (FCS), 100U/mL penicillin and 100µg/mL streptomycin 
(Invitrogen, 15140122) (PS) and 2mmol/L L-glutamine (Invitrogen, 250030081) (DPSC medium). Cells were 
passaged once 80% confluent. 
 
Conditioned media (CM): 
 
Once DPSC were approximately 80% confluent, cells were washed with PBS and given fresh medium. After 
72 hours in culture, the medium was removed and stored at -20oC. Cells were detached and counted using 




An in vitro model of PNNs was used for quick screening. Human embryonic kidney 293T (HEK) cells 
manipulated to express hyaluronan synthase-3 (HAS3) and cartilage link protein-1 (crtl1) (termed HEK-PNN 
cells) were used as they produce a dense PNN-like structure14.  HEK-PNN were cultured in 75cm2 flasks 





CM samples were concentrated by 10 times using centrifuge filtration columns (Millipore, MILUFC801024). 
CM samples were loaded into a 4-12% gradient polyacrylamide gel (ThermoFisher, NP0322BOX) and run 
under reducing conditions.  Following transfer, blots were stained with MMP and ADAMTS antibodies 













CM samples (500μL) were incubated with primary antibodies (table 1) overnight at 4oC on a shaker at 
30RPM. Magnetic bead suspensions (Novex, 10004D) were used to sequester immunocomplexes from the 
solution, as per manufacturer's instructions. Proteins were then eluted using 20μL 0.154mol/L hydrochloric 





Aggrecan (1mg) (Sigma, A1960) was first digested with 1UN of chondroitinase ABC (Sigma, c3667; in 2mL 
0.1M ammonium acetate buffer) overnight at 37oC to remove the attached glycosaminoglycans. This was 
performed to allow MMPs or ADAMTS to act on the core aggrecan protein (figure 1). Aggrecan (1mg) was 
then added to 200μL of CM and incubated overnight at 37oC on a shaker at 30RPM. Aggrecan fragments 
were purified by IP using an antibody specific to the aggrecan-G3 domain (table 1). Aggrecan fragments 




CM (15μL) was separated by electrophoresis on a 10% gelatin-polyacrylamide zymography gel 
(ThermoFisher, EC61752BOX), as per the manufacturer's instructions. Briefly, CM was separated by 
electrophoresis, the enzyme was then renatured and incubated with enzyme reaction buffer. Active 
enzyme digests gelatin in situ, leaving the digested area unstained. Following whole-CM zymography, 
MMP-2 and -8 were purified from CM by IP (table 1) and precipitates were then processed for zymography 
as above. 
 
Digestion of in vitro model of PNNs: 
 
HEK-PNN cells were cultured on glass coverslips until 80% confluent. Media were replaced with 10x CM 
reconstituted in fresh medium and cells were incubated overnight at 37oC. Fresh medium was used as a 
control. Live staining of HEK-PNN was then performed with immunocytochemistry (ICC) antibodies 
described in table 1. Antigen staining intensity and DAPI coverage were quantified algorithmically (Image J 







Brain slice PNN digestion: 
 
Humanely killed mice were scavenged in accordance with The University of Adelaide Animal Ethics 
Committee requirements. Brains were removed and tissue within 2mm of the coronal suture was sliced 
into 1mm frontal sections, which were then incubated in CM or unconditioned medium control for 24 
hours at 37oC. Sections were then fixed with 4% paraformaldehyde overnight at 4oC and snap frozen in 
Tissue Tek® O.C.T. Due to tissue fragility, digested specimens were sliced at 40μm. Slides were stained with 




Graphpad Prism (version 6.05) was used to assess significance, using a one-way ANOVA with Dunnett's 
multiple comparison test. For the quantitation of HEK-PNN digestion, three experimental repeats were 
used to detect a 44% difference between groups with a standard deviation of 4.15%, power of 80% and 







DPSC express active enzymes associated with PNN degradation 
 
In order to investigate the enzyme expression profile of DPSC, conditioned media (CM) collected from DPSC 
culture were interrogated by Western blot (figure 2A). DPSC expressed MMP-1, -2, -7, -8, -9, -13, ADAMTS-4 
and ADAMTS-5. No expression of MMP-14, -19 or -20 was observed. 
 The enzymatic cascades of MMPs and ADAMTS are complex and their activity is tightly controlled. 
To determine the activity of matrix enzymes expressed by DPSC, the CM was incubated with aggrecan, a 
core component of PNNs. Following incubation with CM, the digested fragments of aggrecan were 
immunoprecipitated with an antibody specific to the G3 domain of aggrecan (figure 1B) before being 
separated by SDS-PAGE electrophoresis. Figure 2B demonstrated that incubation with CM resulted in 
multiple bands when visualised using an anti-aggrecan antibody. Major digestion products were detected 
at 42, 31 and 27 kDa, while minor digestion products were detected at 151, 91 and 67 kDa. As fragments 
were purified by IP using a G3 antibody, these fragments suggest MMP cleavage at multiple sites from the 
G3 terminus. The band at 244 kDa represents undigested aggrecan backbone protein. 
 In order to determine the identity of the active matrix-degrading enzymes present in the CM, 
gelatin zymography was performed (figure 2C). The results from this experiment identified a single band of 
72kDa (figure 2). This limits the possibilities to either MMP-2 or MMP-8, which were then isolated by IP and 
again assessed by zymogram. A band was detected following IP of MMP-2 but not MMP-8 (figure 2C). 
 
Enzymes in DPSC CM degrade the PNN 
 
The above results suggested the presence of active matrix-degrading enzymes in DPSC CM. To assess 
whether this enzymatic activity was sufficient to degrade the PNN, we tested the activity in two models: 1) 
an in vitro model of the PNN (Kwok et al., 2010) and 2) murine coronal cortical.  
 The cells expressing PNNs in the in vitro model were digested with CM for 12 hours. The cells were 
then stained with WFA and antibodies specific to aggrecan and Crtl1. CM digestion resulted in a significant 
decrease in WFA staining but no change was detected in aggrecan or Crtl1 (figure 3A-D). 
 To provide a more complete model of brain matrices, fresh murine coronal cortical tissue sections 
were digested with DPSC CM. The results showed that WFA staining was reduced upon incubation with 









We aimed to provide a more complete profile of the enzymes expressed by DPSC. The results 
demonstrated that DPSC express active soluble enzymes capable of digesting core CSPG protein, one of 
which was identified as MMP-2. The activity of soluble enzymes expressed by DPSC was shown to be 
sufficient to digest the PNN both in the in vitro HEK cell model and on adult murine coronal cortical tissue 
slices. 
 In order to navigate through the ECM after transplantation, DPSC must be equipped with ECM 
degrading enzymes. To determine which relevant enzymes were expressed by DPSC, a shortlist of enzymes 
of interest was compiled and assessed for their presence in the CM by Western blot. The results 
corroborate previous studies demonstrating the expression of MMP-1, -2, -13 and -910,11. In addition, we 
have demonstrated the expression of MMP-7, -8, ADAMTS-4 and -5. We did not observe the expression of 
MMP-14 as previously reported by Zheng et al. (2009)11. This is unsurprising as MMP-14 is membrane-
bound and therefore not expected to be present in CM.  
 The proteolytic activity of CM was further demonstrated by aggrecan digestion. Results from 
Western blot showed multiple bands of digestion products, indicating the activity of one or more aggrecan-
degrading enzymes in the CM. As aggrecan is a major component of PNNs, these results imply that DPSC 
may be able to degrade PNNs through the expression of a soluble enzyme. 
 To identify the enzymes responsible for the detected proteolytic activity, CM was assessed by 
gelatin zymography. This is relevant because western blot cannot determine whether enzymes have been 
degraded or whether they are present in an inactive state. Gelatin is a common substrate for the relevant 
enzymes and their ability to degrade gelatin reflects their ability to degrade PNN components. Gelatin was 
degraded in a single band at 72 kDa. Of the enzymes detected Western blot, only MMP2 and MMP8 
corresponded to this molecular weight. Despite being a similar weight, ADAMTS-5 was not considered as it 
does not exhibit gelatinolytic activity15. CM samples were then purified by IP for MMP-2 and MMP-8 and 
the resulting protein was again analysed by zymography. Only MMP-2 was able to demonstrate 
gelatinolytic activity. 
 It is unlikely that MMP2 is the only active matrix enzyme present in CM, primarily because MMP2 
must be activated by other enzymes, such as MMP-1, -3, -7 or -1616.  It is possible that other MMPs are 
present in lower concentrations and that these activate MMP2. Gusman et al. (2002)10 identified active 
MMP-9 expressed in dental pulp, however this was not detected in our investigations. The likely reason for 
this is that Gusman et al (2002)10 studied dental pulp under inflammatory conditions. It is possible that 
certain environmental cues are necessary to stimulate the expression of different MMPs by DPSC. The 
other possibility is that some active MMPs are blocked by tissue inhibitors of metalloproteinase (TIMPs), 
which the present study did not assess. 




activity is sufficient to facilitate degradation of brain extracellular matrices. By using HEK-PNN cells, which 
express a PNN-like structure, we demonstrated that DPSC CM significantly reduced chondroitin sulfate 
staining on the surface of the cells. However, protein components of PNNs (aggrecan and Crtl1) did not 
change. The lack of aggrecanase activity is likely due to steric hindrance presented by chondroitin sulfate 
surrounding the aggrecan core protein. HEK-PNN cells have been previously validated as a human PNN 
model as they express the key PNN components Crtl-1, aggrecan, hyaluronan and HAS3 in a dense structure 
morphologically similar to human PNNs14. 
 MMP activity was further confirmed on murine coronal cortical tissue sections, which are often 
used as a model of human PNNs as these structures are highly conserved among many animal species17–19. 
Following 24 hours of digestion in CM, there was an appreciable decrease in WFA staining, which strongly 
suggests that DPSC express soluble enzymes capable of degrading PNNs and brain matrices. We would 
contend that this may underlie the migratory ability of DPSC when transplanted into the rodent brain4. 
 Condensation of CSPGs into PNNs towards the end of development restricts plasticity in the CNS. 
Enzymatic digestion of chondroitin sulfate in PNNs reactivates plasticity8. In this paper we have 
demonstrated the ability of DPSC to express enzymes capable of degrading CSPGs. This raises the 
hypothesis that our findings may underlie therapeutic efficacy of DPSC transplantation observed in animal 
models of CNS injury2–4.  
 Another important implication of these results is that transplantation of DPSC may destabilise 
existing synapses. The role of PNNs in the adult brain appears to be stabilisation of synapses in network 
traces for vital lifelong behaviours, skills and memories. For example, the appearance of PNNs after the 
critical period for speech development is thought to stabilise the neural networks that encode language, so 
that the skill of language production and interpretation is maintained for life, regardless of ongoing 
reinforcement. Fear conditioning is another learned behaviour thought to be stabilised by PNNs. An 
important recent study has demonstrated that enzymatic degradation of PNNs in adult rats erased a long-
term conditioned fear response20. This suggests that DPSC may also have a destabilising effect on PNN-
protected skills and memories. If this is the case, treatment with DPSC may require the addition of 








The present study demonstrates for the first time that adult human DPSC express active enzymes that are 
capable of degrading PNNs. DPSC CM was shown to degrade an in-vitro model of PNNs and to digest 
aggrecan, a major component of PNNs. Western blot analysis of DPSC CM revealed the expression  MMP-1, 
-2, -13 and -9, ADAMTS-4 and ADAMTS-5. Zymography was used to identify MMP2 in its active form. These 
findings may underlie the migratory ability of DPSC as well as their possible efficacy in the context of stem 






CNS (central nervous system) 
DPSC (dental pulp stem cells) 
SDF1 (stromal-derived factor 1) 
VEGF (vascular endothelial growth factor) 
CXCR4 (chemokine receptor type-4) 
MMP (matrix metalloproteinase) 
ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) 
PNN (perineuronal net) 
FCS (fetal calf serum) 
PS (penicillin and streptomycin) 
CM (conditioned medium) 
HAS3 (hyaluronan synthase 3) 
Crtl1 (cartillage link protein 1) 
ICC (immunocytochemistry)  
IHC (immunohistochemistry) 
IP (immunoprecipitation) 
WFA (Wisteria floribunda agglutinin) 
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Table 1: Antibodies listed were used for western blotting (WB), immunoprecipitation (IP), 





Detected component Product details Use Dilution
MMP1 R&D Systems, MAB901 WB 1:500
MMP2 R&D Systems, MAB 902 IP, WB 1:500, 1:200 IP
MMP7 R&D Systems, MAB9071 WB 1:500
MMP8 Abcam, AB81286 IP, WB 1:1000, 1:200 IP
MMP9 Abcam, AB38898 WB 1:1000
MMP13 Abcam, AB39012 WB 1:3000
MMP14 Abcam, AB51074 WB 1:2000
MMP19 Novus, NB600-1518 WB 1:1000
MMP20 Thermo Scientific, Pa5-13188WB 1:1000
ADAMTS-4 Thermo Scientific, PA1-1750 WB 1:1000
ADAMTS-5 Abcam, ab41037 WB 1:1000
Aggrecan Millipore, ab1031 ICC, IHC, WB 1:400D1, 1:200(IP)
Aggrecan G3 domain Thermo Scientific, PA1-1745 ICC, WB, IP 1:400, 1:200(IP)
WFA Sigma, L1516-2MG ICC, IHC 1:150
Cartilage link protein R&D Systems, AF2608 ICC 1:400
Secondary antibodies
Conjugate Product details Antibody Dilution
Alexa 488 ThermoFisher, S-11223 Streptavidin 1:500
Alexa 568 ThermoFisher, A-11079 Anti-goat 1:500
Alexa 555 ThermoFisher, A-21424 Anti-mouse 1:500
Alexa 488 ThermoFisher A-21204 Anti-mouse 1:500






Figure 1: A) PNNs are a dense matrix composed of hyaluronan (HA), which is tethered to neuronal cell 
membranes by hyaluronan synthase (HAS). Chondroitin sulfate proteoglycans (CSPGs) are bound to HA by 
cartilage link protein 1 (Crtl-1) or brain link protein 1 (Bral-1). Members of the MMP and ADAMTS families 
of enzymes are capable of degrading the protein components of the PNN, while chondroitin sulfate and 
hyaluronan are degraded by members of the hyaluonidase family (HYAL). Adapted from Wang & Fawcett 
(2012)21. B) A schematic showing aggrecan, a widely expressed member of the CSPG family of ECM 
molecules. Glycosaminoglycan (GAG) chains (chondroitin sulfaste and keratin sulfate) are bound to a 







Figure 2: Expression of MMPs in the DPSC CM. A) MMP-1, -2, -7, -8, -9, -13 and ADAMTS-4 and -5 were 
expressed by the three independent DPSC populations (H1-H3; n=3). B) Representative image of aggrecan 
digested by the CM (n=9 replicates). C) Zymography was used to demonstrate enzyme activity in whole CM 





Figure 3: A-D provide a quantification of ICC of HEK-PNN cells digested in CM. N=3 for each DPSC sample 
(H1-H6). E-F are representative examples from n=9 experimental replicates of murine coronal cortical 
sections undergone immunohistochemistry showing WFA (green) counterstained with DAPI (blue) following 
digestion with control medium (E) or CM (F). n=9 experimental replicates. G quantifies the staining intensity 
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Perineuronal nets (PNNs) are specialised regions of condensed extracellular matrix surrounding neuronal 
cell bodies and proximal processes. The main function of PNNs is to inhibit neuronal reorganisation in adult 
brains. Ischaemic stroke causes the loss of large numbers of neurons that cannot be fully regenerated, 
resulting in chronic cognitive and motor/sensory disturbances. The months following stroke are 
characterised by a limited period of enhanced capacity for neuronal reorganisation and functional recovery. 
There is limited evidence that this effect is the result of a downregulation of PNN components. The present 
study aimed to characterise endogenous changes in the expression of key components of PNNs in an 
experimental model of stroke. Mice were subject to photochemical ischaemia prior to being euthanized at 
regular intervals up to nine weeks post-stroke. Expression of WFA-binding glycans, aggrecan, chondroitin 4-
sulfate (CSA), hyaluronan, cartilage link protein and tenascin-R was assessed in different cortical locations by 
immunohistochemistry. The results demonstrated that stroke is immediately followed by a downregulation 
of PNNs in the area contralateral to the lesion and an upregulation of CSA in the ischaemic border zone. 
WFA and aggrecan staining then increased gradually towards baseline, while CSA staining decreased 
towards baseline. These results are consistent with the hypothesis that post-stroke enhancement of 





Perineuronal nets (PNNs) are specialised regions of extracellular matrix that predominantly surround the 
soma and proximal processes of inhibitory interneurons in the cortex, basal nuclei and the spinal cord 
(Karetko & Skangiel-Kramska 2009; Galtrey et al. 2008). Microscopically, PNNs appear as a mesh 
surrounding the soma and proximal processes of neurons, interrupted by sites of axonal and glial contact. 
 
At a molecular level, PNNs are composed of hyaluronan (HA) chains tethered to neurons by hyaluronan 
synthase. Chondroitin sulfate proteoglycans (CSPGs) are bound to HA at their N-termini by cartilage link 
protein (Crtl1) or brain link protein. Tenascins provide further stability to PNNs by each binding up to three 
CSPGs at their C-termini (Wang & Fawcett 2012; Yamaguchi 2000). 
 
The physiological function of PNNs is thought to be associated with the inhibition of synaptogenesis and the 
stabilisation of existing synapses in the adult CNS. The first clue pertaining to the function of PNNs lies in 
the timing of their appearance during development. This time also marks the termination of a period of 
enhanced neuroplasticity during which all basic motor and sensory skills must be acquired, termed critical 
periods (Carulli et al. 2007). 
 
Further evidence for the role of PNNs in inhibiting adult neuroplasticity is demonstrated in animal models. 
Transgenic mice lacking Crtl1 do not develop mature PNNs and show an extension of the ocular dominance 
critical period into adulthood as well as spontaneous axonal sprouting into lesioned areas (Carulli et al. 
2010). Disruption of PNNs has been achieved in adult animals by treatment with ABC chondroitinase, which 
digests HA and the glycosaminoglycan (GAG) chains of CSPGs. García-Alías et.al. (2009) showed that 
treatment with chABC in conjunction with rehabilitation resulted in functional recovery in a rat model of 
cervical spinal cord injury. 
 
The presence of PNNs alone is not a sufficient predictor of inhibition of neuroplasticity, but rather their 
specific composition appears to play a significant role in determining function. The sulfation states of GAGs 
in particular seem to determine their activity. Prior to the termination of critical periods, primordial PNNs 
contain a high proportion of chondroitin 6-sulfate (CSC) as compared with chondroitin 4-sulfate (CSA) 
(Carulli et al. 2010). Coinciding with the decrease in plasticity following critical periods, the ratio of CSA:CSC 
increases (Miyata et al. 2012). Additionally, Miyata and Kitagawa (2012) demonstrated that transgenic 
animals maintaining a low CSA:CSC ratio show significant delay in the termination of ocular dominance 
critical periods. This suggests that the presence of PNNs enriched with CSA inhibits neuroplasticity, while 




The postulated mechanisms by which PNNs exert their inhibitory effect include the formation of a physical 
barrier to new synapse formation by occupying areas of neuronal membrane, that PNN components are 
directly inhibitory against axonal outgrowth and that PNNs sequester and present inhibitory axon guidance 
molecules (Vo et al. 2013; Apostolova et al. 2006). The role of CSA in PNN activity is likely structural as 
transgenic mice that maintain a high proportion of CSC fail to develop condensed PNNs (Miyata et al. 2012). 
 
The role of PNNs in the regulation of adult neuroplasticity makes them an attractive therapeutic target for 
the treatment of ischaemic stroke. The mechanisms of action for all extant stroke therapies rely on 
minimising the extent of ischaemic damage. Modulation of PNNs may enhance neuroplasticity. In 
combination with rehabilitation, PNN disruption may allow patients to compensate with existing brain 
tissue and recover lost function beyond what can be achieved with rehabilitation alone. However, in order 
to develop this type of therapy, the function of PNNs in the context of ischaemic stroke must first be 
understood. 
 
There is evidence that PNNs are modified in response to external stimuli. Loss of sensory input and 
environmental enrichment both cause a decrease in expression of PNNs in specific areas of cortex (McRae 
et al. 2007; Sale et al. 2007), while damaging stimuli cause a more complex response. The development of a 
glial scar surrounding the borders of a mature ischaemic lesion has been well-characterised (Hobohm et al. 
2005). The components of a glial scar bear a marked resemblance to those of PNNs and perform the same 
inhibitory function (Harris et al. 2009). However, occurring concurrently with the increase in expression of 
PNN components in the glial scar, Hobohm et al. (2005) showed a decrease in PNN expression in areas distal 
to the infarct. This study posited that the loss of PNNs may underlie post-stroke loss of function, however 
the current understanding of the inhibitory functions of PNNs suggests that this response to stroke may be 
part of a mechanism to regain function. Similarly, Harris et al. (2009) showed that CSPGs associated with 
both PNNs and extracellular matrix (ECM) were upregulated in the glial scar surrounding a traumatic brain 
injury, but downregulated in the distal ipsilateral regions. These findings were corroborated by Karetko-Sysa 
et.al. (2011), who showed a decrease in PNN density following cortical photothrombosis in rats. 
 
Endogenous modification of PNNs may underlie the observation that stroke patients experience a 
temporary period of enhanced neuroplasticity. Spontaneous recovery of cognitive and motor-sensory 
function occurs rapidly in the first few months following a stroke and plateaus thereafter. For example, most 
recovery from visuospatial neglect occurs within the first 12-14 weeks (Nijboer et al. 2013), recovery of 
upper limb motor deficits occurs within nine weeks (Jørgensen et al. 1995) and the majority of spontaneous 
recovery of language function occurs within six weeks (Pedersen et al. 1995). Task-specific rehabilitation can 
produce further recovery (Tombari et al. 2004), but any abilities that remain lost beyond this initial period 
do not demonstrate further spontaneous recovery without intervention and are often lost in perpetuity. 
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Furthermore, Hsu et al. (2005) demonstrated that a unilateral stroke enhanced learning in the contralateral 
hemisphere in rats. This time course for stroke recovery suggests a critical period of enhanced plasticity. 
Given the function of PNNs and their known propensity to alter in response to changing environmental 
stimuli, it is possible that post-stroke enhanced neuroplasticity is accommodated by either a global decrease 
in PNN density or a shift towards a low CSA:CSC ratio. 
 
The literature demonstrates that following focal cerebral injury, inhibitory ECM components are 
upregulated in the glial scar and downregulated in distal areas. Numerous studies have assessed the 
expression of different markers of PNNs, including WFA-binding glycans and CSPG core proteins. These 
studies have used different methods of inducing a focal lesion and have noted a decrease in PNNs up to 14 
days after the insult. This study aims to characterise changes in the spatial expression of the major 
components of PNNs and sulfation of GAGs following stroke and to detect trends in their expression levels 
over time. This information can be used to inform the design of therapies that target PNNs to improve the 








Male C57BL6 mice aged six months were obtained through the University of Adelaide Laboratory Animal 
Services. Approval was granted by the University of Adelaide animal ethics committee (M-2013-166). 
 
Determination of handedness: 
Handedness in mouse populations varies with approximately 50% preferring either paw. Handedness was 
determined for each mouse prior to induction of photochemical ischaemia by using a skilled reaching 
assembly previously described by Whishaw et al. (1990). Briefly, a small chamber was constructed from 
opaque acrylic plastic with a transparent window at the front containing a 10mm aperture through which 
the mice could reach and grasp for pellets of food. The aperture was small enough that only one paw could 
be used at a time. Mice were fasted overnight prior to testing and then given 20 pellets consecutively. The 
paw used to grasp the most pellets was recorded as the preferred paw. 
 
Photochemical stroke model: 
Ischemic stroke was modeled using the photochemical method described by (Watson et al. 1985). Rose 
Bengal dye (Sigma, R3877) was prepared fresh as needed at 10mg/mL in normal saline and then filtered 
through a 0.45um filter (minisart, Sartorius). Mice were administered Rose Bengal solution via an 
intraperitoneal injection at a dose of 100mg/kg. Ten minutes was allowed for the dye to perfuse into 
systemic circulation. The mice were anaesthetised with isoflurane in a sealed induction box, then secured in 
a stereotaxic frame while a maintenance dose of isoflurane was provided via a nose cone. A sagittal incision 
was made from the interparietal bone to the mid-orbital point to expose the cranium. The stereotaxic frame 
was used to locate the point 1.5mm lateral to bregma on the side contralateral to the preferred paw. This 
point lies over the primary motor region for the dominant forepaw. A 500-570nm cold light source at 240 
lumens was directed through a 2.5mm aperture centered on the point located. The light source was 
removed after ten minutes. Mice in the sham stroke group were subject to the same surgical procedure and 
the same dose of Rose Bengal, but the light source was never switched on. Allocation of mice to stroke or 
sham group was randomized by computer. 
 
After the procedure, the scalp incision was sutured and treated with topical mupirocin (Bactroban®, GSK). 
An epidermal injection of 50µl 0.5% bupivacaine hydrochloride was administered at the site of the incision 
to prevent discomfort. The mice were allowed to recover in a dark, heated box and were given enriched 
feed. The well-being of the mice was assessed three times daily for the first week post-surgery and daily 






A total of 15 mice were humanely killed by deep anaesthesia with isoflurane at one, three, five, seven or 
nine weeks post-stroke (Figure 1B). Allocation of mice to different time cohorts was not randomized. A 
longitudinal incision was made from the manubrium to the umbilicus, then the ribs were cut bilaterally at 
the mid-clavicular line and the diaphragm was removed to expose the mediastinum. A small incision was 
made in the right ventricle of the heart, while PBS was infused into the left ventrical at constant pressure. 
When exsanguination was complete, a 4oC solution of 4% paraformaldehyde (PFA) in normal saline was 
infused into the left ventrical. 
 
The brain was then removed and placed in a solution of 4% PFA in normal saline for 24 hours. The PFA 
solution was then removed by washing the brain in normal saline three times for 30 seconds. The brain was 
placed in a solution of 30% sucrose in normal saline for 24 hours to cryopreserve the tissue for sectioning. 






Slides containing brain sections were washed in 0.03% Triton-X 100 (Sigma, T8787) in phosphate buffered 
saline (PBS) (washing buffer) three times for five minutes each. Slides were then blocked with 3% normal 
horse serum in washing buffer (blocking buffer) for one hour at room temperature. Slides being probed for 
CSA underwent an additional blocking step with 0.1mg/mL unconjugated affinity purified F(ab) fragment 
anti-mouse IgG in PBS for 30 minutes.  After blocking, the slides were incubated with primary antibodies in 
blocking buffer overnight at 4oC. Control slides were incubated in blocking buffer without primary 
antibodies. The slides were returned to room temperature over 30 minutes, then washed three times for 
five minutes each in washing buffer. Secondary antibodies in blocking buffer were applied and slides were 
incubated at room temperature for two hours. The slides were incubated with DAPI (1x, ThermoFisher, 
D1306) in blocking buffer for five minutes, then washed three times for five minutes each in washing buffer. 
Coverslips were applied to the slides with gold antifade mounting medium (ProLong®, ThermoFisher, 
P36930). 
 
Primary antibodies were chosen to detect chondroitin sulfate A (1:100, United Bio Research, CAC-NU-07-
001), aggrecan (1:100, Millipore, AB1031), Cartilage link protein 1 (Crtl1) (1:200, Abcam, ab181997), 
wisteria floribunda agglutinin (WFA)-binding glycans (1:100, Sigma, L1516-2MG), hyalauronan (1:100, 
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United Bio Research, HKD-BC41) and tenascin-R (1:100, Abcam, ab198863). Secondary antibodies were 
alexa 488 anti-mouse, Cy3 anti rabbit and strepavidin-conjugated alexa 548. 
 
Microscopy: 
Panoramic micrographs of each brain slice were taken at 40x magnification. Microscopy was conducted with 
a Nikon® Eclipse Ni-E microscope and micrographs were captured using a Nikon® DS-Qi2 camera. Exposure 
time and excitation intensity were set using staining control slides and were kept constant for each antibody 
combination. 
 
Quantitation and statistics: 
Quantitation of micrograph data was done using ImageJ (version 1.49, NIH). Coronal brain section 
micrographs were divided into sections representing the infarct core, the ischaemic border zone (IBZ), the 
ipsilateral hemisphere and the equivalent areas in the contralateral hemisphere. The infarct core was 
outlined manually and was defined by the border of the acellular region. The IBZ was defined as an area 1.5 
times as large as the infarct core, beginning at the outer edge of the cortex. The cortex was defined as the 
rest of the cortex not included in the infarct core or IBZ. The equivalent areas on the contralateral 
hemisphere were identified by transposing a horizontally mirrored version of the selection mask onto the 
unaffected hemisphere. These areas are outlined in Figure 1A. 
 
DAPI staining was used to determine a cell count within each area of the brain slices. Mask thresholds and 
particle parameters were kept constant for all images. Staining intensity for each of the PNN components 
was determined within each area of the brain slices. While outcome assessment was mainly algorithmic, 
this was not conducted by a blinded operator. 
 
Statistical analyses were carried out using Prism (version 7.02, Graphpad). Comparisons between the 







Histological outcomes of photochemical ischaemia: 
 
A total of 15 mice were used in this study. The original project design called for the confirmation of stroke 
induction by observing circling behavior and limb paresis, however the majority of mice did not display 
obvious signs of stroke. Therefore, all mice were included in the study and presence of an infarct was 
confirmed later by histology.  
 
Characteristic changes were seen in DAPI staining of cortical tissue from all mice that underwent 
photochemical ischaemia. Tissue corresponding to the area of illumination became anuclear by seven days 
post-infarct. The ischemic core was replaced by a cavity 21 days post-infarct and showed some contraction 
when compared to earlier samples. From 35 days onward, the lesions had contracted significantly and were 
surrounded by scar tissue that was denser than the surrounding parenchyma. These changes are evident in 
Figures 2-7. 
 
Changes in the spatial expression of PNN components: 
 
The expression of total PNNs following photochemical ischaemia was visualised using WFA lectin 
histochemistry (Figure 2). In the sham stroke group, WFA-binding GAGs were strongly expressed in two 
cortical layers. Staining morphology revealed punctate PNNs surrounding soma and short neurite segments 
on a background of diffuse staining consistent with loose ECM. One week following photochemical 
ischaemia, individual PNNs were no longer visible in either cortex. Dense staining was seen within the 
infarct, but this did not suggest expression surrounding cells with neuronal morphology and appeared to be 
associated with necrotic debris. By three weeks a region of dense WFA staining was visible in the 
perilesional region. From five weeks onwards, PNNs appeared first in areas distant to the infarct. By week 
nine, normal PNN distribution was seen throughout the cortex. 
 
Aggrecan is the most ubiquitous CSPG component of PNNs. Immunohistochemistry was conducted to 
visualise the response of aggrecan to photochemical ischaemia (Figure 3). In the sham group, aggrecan was 
strongly expressed in two cortical layers, which is similar to the staining pattern of WFA. Dense, punctate 
regions of aggrecan surrounded the soma and proximal processes of cells with a neuronal appearance in 
these cortical regions. Following stroke, aggrecan-containing PNNs were completely abolished in both 
cortices and diffuse staining was also reduced. There was some dense staining with non-neuronal 
morphology within the lesion that was not consistent with PNNs. Aggrecan-containing PNNs were visible 
again from week five post-stroke, being denser in the contralesional cortex. By nine weeks post-stroke, 
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aggrecan-containing PNNs of normal morphology were plentiful in both hemispheres, but appeared sparser 
in the region surrounding the infarct.  
 
CSA is the type of CSPG GAG sidechain most inhibitory to neurite outgrowth and synaptic plasticity. 
Immunohistochemistry was used to assess CSA expression following photochemical ischaemia (Figure 4). 
Compared with WFA and aggrecan, CSA staining was diffuse and did not demonstrate a punctate, neuronal 
morphology. One week after photochemical ischaemia, CSA expression was more intense in the IBZ and was 
still diffuse. By three weeks post-stroke hyperintense perilesional staining had taken on a spiculated 
appearance, with expression suggesting projections radiating out from the infarct. Over the course of the 
study, CSA staining intensity in the IBZ decreased towards baseline. 
 
Crtl1 is a critical component of PNNs that links CSPGs with their hyaluronan scaffold. Immunohistochemistry 
was used to investigate Crtl1 expression following photochemical ischaemia (Figure 5). In the sham group, 
Crtl1 staining was seen throughout the cortical layers. Dense Crtl1 staining surrounded soma, but there was 
no visible staining of neurites. Crtl1-containing PNNs were abolished in weeks 1-3, with some nonspecific 
staining within the lesion boundary. At five weeks post-stroke, PNNs containing Crtl1 were apparent in the 
contralesional hemisphere, but were still absent in the ipsilesional hemisphere. At nine weeks post-stroke, 
Crtl1 staining revealed only sparse PNNs visible in the ipsilesional hemisphere.  
 
Tenascin-R is a stabilising component of PNNs that binds the C-termini of CSPGs. Immunohistochemistry 
was used to characterise changes in Tenascin-R expression following photochemical ischaemia (Figure 6). In 
the sham group, tenascin-R staining was diffuse and did not reveal a characteristic PNN morphology. 
Staining intensity appeared to be globally upregulated in weeks 1-3 post-stroke. From week five onwards, 
Tenascin-R staining intensity was indistinguishable from baseline and no change in morphology was seen. 
 
Chains of hyaluronan anchor to neuronal cell membranes and form scaffolds for the other PNN 
components. Hyaluronan binding protein was used to visualise changes in hyaluronan expression following 
photochemical ischaemia (Figure 7). In tissue from the sham group, hyaluronan staining was diffuse and 
was not specifically associated with soma or neurites. No change in staining intensity or morphology was 
seen in weeks 1-3 post-stroke. In one sample, hyaluronan staining intensity in the perilesional region 
appeared to increase at five weeks, but this was not consistent. Staining in weeks 7-9 post-stroke was 







Quantitation of Immunohistochemistry 
 
Two-way ANOVA demonstrated a significant decrease in aggrecan staining in the area contralateral to the 
ischaemic core and IBZ at early post-stroke time points, as compared with the control group. This was 
followed by an increase in aggrecan staining at later time points. CSA staining intensity was significantly 







This study aimed to characterise changes in the expression of key PNN components following an 
experimental model of focal ischaemic stroke in mice. The results indicate that following stroke, there is an 
acute and temporary decrease in the expression of Crtl1, aggrecan and other WFA-binding glycans in the 
area contralateral to the ischaemic core. Whilst no significant increase in aggrecan or WFA binding glycans 
was detected in the IBZ, there was a marked enrichment of CSA in this area. Over the course of observation, 
WFA binding glycans and aggrecan increased towards baseline levels. CSA expression in the IBZ decreased 
towards baseline. This study did not identify any change in the expression of hyaluronan, or TNR. 
 
WFA binds GAG chains associated with ECM and is commonly used as a marker for PNNs. This stain does 
not enable interrogation of the specific composition of PNNs, but provides an overview of PNN density. 
Global WFA staining appeared to diminish one week post-stroke as compared with the control group and 
morphologically characteristic PNNs were almost completely abolished (figure 2). Statistical analysis of 
quantitation determined that diminished WFA staining at week one was only significant in the areas 
contralateral to the ischaemic core and IBZ (Figure 8), though there was a tendency towards this change in 
all areas. Over time, WFA staining increased towards baseline. In sham group tissue, PNNs surrounded the 
soma and proximal neurites of cells in two distinct cortical layers, which is consistent with previous 
descriptions of PNN distribution (Karetko-Sysa et.al. 2011; Karetko & Skangiel-Kramska 2009). These 
findings suggest a temporary decrease in the expression of PNNs after ischaemic stroke, which may be more 
pronounced in the contralesional homotopic region.  
 
Aggrecan core protein is the most ubiquitously expressed of the CSPGs, which comprise the major 
functional components of PNNs. Expression of aggrecan decreased during weeks 1-3 post-stroke (figure 3). 
Interestingly, most of the reduction in aggrecan expression was seen in the area contralateral to the infarct 
core and IBZ (Figure 8). This is consistent with previous findings that demonstrated a decrease in cortical 
expression of aggrecan following photochemical infarction (Karetko-Sysa et al. 2011) and focal traumatic 
brain injury (Harris et al. 2009), which shares a similar pathophysiological course with ischaemic stroke. The 
gradual return to baseline expression levels of aggrecan is also consistent with these previous findings, 
though our results suggest that this occurs over a period of nine weeks as opposed to the 14-30 days. 
Possible reasons for this discrepancy are species differences and differences in lesion methodology. Harris 
et al. (2009) investigated aggrecan in a rat model, while Karetko-Sysa et al. (2011) used a variation of the 
photochemical ischaemia protocol with a smaller aperture and a longer illumination time. Given that 
aggrecan is a widely expressed member of the family of CSPGs that are essential components of PNNs, our 
results suggest that cerebral ischaemia is followed by an acute, temporary decrease in cortical PNN density 




CSA is the main neurite-outgrowth inhibitory GAG component of PNNs and a low CSA:CSC ratio is associated 
with increased neuroplasticity (Carulli et al. 2010; Miyata et al. 2012). Cortical expression of CSA in the 
sham group showed a similar pattern to WFA, though at higher magnification CSA staining surrounding 
soma was more diffuse and did not have an obvious branching morphology (Figure 4). This is similar to the 
appearance of CSA expression in the brains of adult rats (Foscarin et al. 2017). Following stroke, a marked 
enrichment of CSA was detected in the IBZ (Figure 8). In weeks 1-3 post-stroke, distinct regions of CSA 
associated with soma were no longer visible in either cortex, though this effect was not robust enough to be 
detected by quantitation. CSA enrichment in the IBZ decreased towards baseline over the course of the 
study. As CSA is inhibitory to neurite outgrowth, its enrichment in the IBZ may represent a component of 
glial scars. These structures develop in the regions surrounding infarcts and are inhibitors of neurite 
outgrowth containing some of the same CPSGs as PNNs (McKeon et al. 1999; Harris et al. 2009). This 
hypothesis could be tested by assessing colocalization of CSA and glial fibrillary acidic protein (GFAP) in the 
IBZ following stroke, as GFAP is a marker of gliosis. Previous studies have also demonstrated an enrichment 
of CSC and 4,6-O-CS (CSE) in the glial scar following TBI (Gilbert et al. 2005). It is likely that as in the 
developing brain, the ratio of these CS subtypes may underlie the inhibitory capacity of the glial scar. 
 
Crtl1 is a critical component of PNNs and its expression appears to trigger PNN formation in development 
(Kwok et al. 2010; Carulli et al. 2010). Results from immunohistochemistry of sham stroke mouse brains 
show pan-cortical expression of Crtl1 (Figure 5). Dense regions of staining surrounded soma but did not 
appear to surround dendrites. These formations were obliterated following stroke and returned first in the 
contralesional hemisphere after 5 weeks. Punctate Crtl1 staining in the region surrounding the stroke was 
visible after nine weeks, but did not appear as intense as the contralesional cortex. These changes in 
expression were a qualitative impression only as the staining method was not sufficiently robust to 
demonstrate the effect quantitatively.. These results reflect an effect demonstrated by Carulli et al. (2010), 
who showed that sensory deprivation of mice caused a reversible decrease in Crtl1 expression. In the 
present study, ipsilesional reduction of Crtl1 may be caused by deafferentation of brain regions that 
received inputs from the infarcted region. 
 
TN-R facilitates cross-linking of lecticans, which stabilises PNNs. Its expression forms a major step in the 
maturation of PNNs in development (Guntinas-Lichius et al. 2005). Results from immunohistochemistry did 
not demonstrate a change in TN-R following photochemical infarction (Figures 6,8). As TN-R has an affinity 
for CSPG core proteins, it was expected that TN-R staining would follow the same post-stroke pattern of 
attenuation as aggrecan. One reason this was not seen may be that its association with loose ECM masked 





Hyaluronan is the major structural component of PNNs. It is attached to neuronal cell membranes through 
hyaluronan synthases and provides a loose scaffold onto which CSPGs can bind and organise into a dense 
lattice. Staining intensity appeared to increase following stroke, particularly in the IBZ (Figure 7), though this 
did not reach statistical significance (Figure 8). Earlier findings also showed that hyaluronan expression was 
upregulated following stroke, though these results were obtained through western blot rather than 
immunohistochemistry (Al Qteishat et al. 2006). One reason that significant changes in hyaluronan-
containing PNNs were not detected is that hyaluronan staining was very diffuse and did not clearly localize 
to PNNs (Figure 7). Staining for hyaluronan synthases instead may provide better imaging for quantitation as 
these proteins localise to cell membranes (Al Qteishat et al. 2006). Additionally, changes in PNNs may occur 
independently of hyaluronan as this is not an active contributor to neurite outgrowth inhibition. Hyaluronan 
alone is not sufficient for functional PNNs and it has been shown to be present in inactive PNN precursors 
(Kwok et al. 2010; Carulli et al. 2007). 
 
The ability of this study to resolve smaller changes in the expression of hyaluronan, Crtl1 and TNR could be 
improved with a larger sample size at early time points. To provide adequate data for analysis by ANOVA, 
data were grouped into control, weeks 1-3, weeks 5-7 and week 9. While this provided a robust analysis of 
long-term trends, it also meant a loss of temporal resolution. 
 
It has been observed that stroke patients experience a temporary increase in neuroplasticity that conveys 
the potential for rapid functional recovery (Bonita & Beaglehole 1988; see Murphy & Corbett 2009; Dimyan 
& Cohen 2011 for review). The main function of PNNs is to inhibit neuroplasticity and artificial removal of 
PNNs results in a period of increased neuroplasticity like that seen in juveniles prior to the termination of 
critical periods (Soleman et al. 2012; Carulli et al. 2007; García-Alías et al. 2009). The present study 
demonstrated a temporary downregulation of aggrecan and other WFA-binding components of PNNs. 
Therefore, a likely hypothesis is that the period of increased plasticity that accompanies recovery from 
ischaemic stroke is the result of a decrease in the expression of these components. In particular, the marked 
reduction in aggrecan expression in the contralateral hemisphere may represent a mechanism to 
compensate for lost cortical regions by relocating their function to their contralateral equivalent. This 
phenomenon of function relocation has been observed in functional MRI studies of stroke patients (Carey 
et al. 2002; Abo et al. 2001; Staudt 2002). Furthermore, artificial disruption of PNNs after stroke has been 
shown to increase branching from the contralesional hemisphere (Soleman et al. 2012). The role of 
endogenous PNN alteration in cortical function relocation remains to be investigated. 
 
This study characterised spatial and temporal changes in the expression of PNN components following focal 
ischaemic stroke in mice. Specifically, staining for WFA binding glycans and aggrecan underwent 
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modifications consistent with decreased inhibition to neuronal plasticity. These changes may underlie a 
mechanism for a temporary post-stroke enhancement of neuroplasticity. Future research into potential 
stroke therapies should focus on extending the post-stroke period of enhanced neuroplasticity. This may be 
achieved by artificially enhancing the endogenous post-stroke reduction in PNN density observed here. 
Current methods for achieving this include digestion with ABC chondroitinase (Soleman et al. 2012; García-
Alías et al. 2009) or members of the matrix metalloproteinase family (our unpublished results). This strategy 







Figure 1: A) Coronal brain sections were divided into areas for quantitation and analysis. ICc is the area 
contralateral to the infarct core, IBZc is the area contralateral to the ischaemic border zone, Cc is the 
contralateral cortex, ICi is the infarct core, IBZ is the ischaemic border zone and Ci is the ipsilateral cortex. As 
the infarct core is acellular, this area was left out of analysis. B) Experimental timeline. Mice were humanely 
killed 1, 3, 5, 7 and 9 weeks after photochemical ischaemia or sham surgery. Brains were then sectioned and 






Figure 2: Distribution of total PNNs following photochemical ischaemia. PNNs were detected through their 
WFA-binding lectin component (green) and nuclei were detected with DAPI (blue). Photochemical lesions 
are located on the left of each section. Higher power magnifications of WFA staining of the infarct and the 
contralateral cortex are displayed in greyscale to improve visual contrast. The locations of the higher-power 
magnification images are indicated by green boxes in the low-power counterstained images.  Images are 
representative of n=5 in the sham group, n=3 at week 1, n=1 at week 3, n=3 at week 5, n=3 at week 7 and 






Figure 3: Response of aggrecan core-protein expression to photochemical ischaemia. Immunofluorescence 
staining shows aggrecan (green) and DAPI (blue). Photochemical lesions are located on the left of each 
section. Higher power magnifications of aggrecan staining of the infarct and the contralateral cortex are 
displayed in greyscale to improve visual contrast. The locations of the higher-power magnification images 
are indicated by green boxes in the low-power counterstained images.. Images are representative of n=5 in 







Figure 4: Expression of 4-O-sulfated chondroitin (CSA) following photochemical ischaemia. 
Immunofluorescence staining shows CSA (green) and DAPI (blue). Photochemical lesions are located on the 
left of each section. Higher power magnifications of CSA staining of the infarct and the contralateral cortex 
are displayed in greyscale to improve visual contrast. The locations of the higher-power magnification 
images are indicated by green boxes in the low-power counterstained images.. Images are representative of 







Figure 5: Expression of Crtl1 following photochemical ischaemia. Immunofluorescence staining shows Crtl1 
(green) and DAPI (blue). Photochemical lesions are located on the left of each section.  
Higher power magnifications of Crtl1 staining of the infarct and the contralateral cortex are displayed in 
greyscale to improve visual contrast. The locations of the higher-power magnification images are indicated 
by green boxes in the low-power counterstained images.. Images are representative of n=5 in the sham 







Figure 6: Expression of Tenascin-R following photochemical ischaemia. Immunofluorescence staining shows 
Tenascin-R (green) and DAPI (blue). Photochemical lesions are located on the left of each section.  
Higher power magnifications of Tenascin-R staining of the infarct and the contralateral cortex are displayed 
in greyscale to improve visual contrast. The locations of the higher-power magnification images are 
indicated by green boxes in the low-power counterstained images.. Images are representative of n=5 in the 







Figure 7: Expression of hyaluronan following photochemical ischaemia. Immunofluorescence staining shows 
hyaluronan (green) and DAPI (blue). Photochemical lesions are located on the left of each section.  
Higher power magnifications of hyaluronan staining of the infarct and the contralateral cortex are displayed 
in greyscale to improve visual contrast. The locations of the higher-power magnification images are 
indicated by green boxes in the low-power counterstained images.. Images are representative of n=5 in the 







Figure 8: Immunohistochemical staining intensity for each PNN component (y-axes) was quantified in the 
five locations specified (x-axes) in three time periods post-stroke. Data were expressed as mean ± standard 








PNN  Perineuronal Net 
WFA  Wisteria Floribunda Agglutinin 
CSA  Chondroitin Sulfate A | Chondroitin 4-sulfate 
HA  Hyaluronan 
CSPG  Chondroitin Sulfate Proteoglycan 
GAG  Glycosaminoglycan 
CSC  Chondroitin Sulfate C | Chondroitin 6-sulfate 
CSE  Chondroitin Sulfate E | Chondroitin 4,6-sulfate 
ECM  Extracellular Matrix 
PFA  Paraformaldehyde 
IBZ  Ischaemic Border Zone 
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Chapter 4 Supplement 1 
 
 
Supplementary figure 1: Nonspecific staining was controlled for by omitting the primary antibodies or 
binding proteins from the protocol. A) Alexa 458-Streptavidin only was used to control for biotinylated WFA 
and hyaluronan binding protein stains. B) Cy3 anti-rabbit only was used to control for Aggrecan, Crtl-1 and 
tenascin-R staining. C) Alexa 488 anti-mouse only was used to control for CSA staining. All micrograph 








Supplementary figure 2: Higher magnification images from figures 2-5 demonstrating staining morphology 
of PNN components around individual cells at selected timepoints. WFA and aggrecan staining was 
concentrated around soma and short segments of cell processes. CSA staining was more diffuse, but also 
appeared more intense around soma and processes. Crtl-1 staining surrounded soma but did not appear to 
surround processes. Hyaluronan and Tenascin-R staining examples are not shown as these were diffuse and 
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Ischaemic stroke lacks a medical intervention to restore lost cognitive and sensory motor function in the 
chronic phase of recovery. To investigate potential interventions that may fill this gap in treatment, a 
protocol must be designed to produce a model of stroke that is reproducible, technically accessible and 
that accurately models the chronic phase of stroke in humans. In this study, a photochemical protocol was 
used to create ischaemic lesions in aged mice. The resultant lesions were imaged at regular intervals using 
MRI and histology, which together demonstrated that the patterns of organisation following photochemical 
infarction mimic the pathophysiological course in ischaemic stroke. Behaviour testing showed a marked 
decline in the function of the targeted forepaw up to two weeks following photochemical infarction, but 
failed to detect the long-term functional deficits that are required in a model of chronic stroke. Future 
optimisation of this protocol will contribute to the development of treatments for the unmet need of 





Ischaemic stroke is an increasingly common cause of long-term intellectual and sensory-motor disability. 
Approximately 1.8% of the Australian population reports to have suffered a previous stroke and of these, 
35% report suffering chronic disability as a result1. Current medical interventions for stroke include 
intravenous thrombolysis2, endovascular thrombectomy3,4, decompressive hemicraniectomy5, stroke unit 
care6 and prophylactic anticoagulation7,8. The mechanisms for these interventions are biased towards the 
acute period of stroke pathophysiology and act with a view to limit the extent of damage caused by 
ischaemia and prevent future stroke events from occurring. While primary and secondary prevention 
should be the focus, there is a dearth of active biological agents to overcome the chronic disability caused 
by stroke. 
 
The ability to recover lost function following stroke appears to be temporarily enhanced by endogenous 
mechanisms9,10. The goal of stroke research should be to enhance the extent of recovery following stroke. 
Methods of achieving improvements in long-term outcomes for stroke patients will need to focus on either 
reversing the neuro-anatomical damage caused by the stroke or by modifying the surviving brain to better 
compensate for damage. Potential treatment modalities that have been explored to date include 
transplantation of stem or progenitor cells11–14, which is thought to act through bystander effects15, and 
enhancement of neuroplasticity through a combination of interruption of inhibitory mechanisms, such as 
the perineuronal net16, semaphorin17 and Nogo systems18–20, and rehabilitation. 
 
In order to fully investigate these potential treatment modalities, we require a highly reproducible, 
pathophysiologically accurate and technically straightforward model of chronic ischaemic stroke. Common 
methods of stroke induction in animals include middle cerebral artery (MCA) occlusion (MCAo), endothelin-
1 vasoconstriction, microembolus injection, and photochemical ischaemia. 
 
Up to this point, the gold-standard model for ischaemic stroke has been MCAo in rodents21. This model 
involves gaining access to the MCA via the internal carotid artery, then temporarily occluding the origin of 
the MCA. Reperfusion occurs instantly when the occlusion is removed, as opposed to the gradual 
reperfusion that occurs following endogenous clot lysis. This arguably makes MCAo a more accurate model 
of intravascular thrombectomy than it is of untreated stroke or stroke treated with intravenous 
thrombolysis. MCAo is a highly invasive and intricate procedure analogous to human microvascular surgery. 
Small differences in technique and vascular anatomy can result in both inter- and intra-operator variation in 
stroke size, lesion location, behavioural outcomes and well-being of the animals used22. Other factors that 
affect the suitability of this technique include the potential for spontaneous subarachnoid haemorrhage23 
and dysphagia resulting from ligation of the external carotid artery24. 
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The endothelin-1 stroke model involves infusion of endothelin-1, a potent vasoconstrictor, into the MCA. 
This results in the formation of ischaemic lesions of highly variable size and location anywhere within the 
vascular territory of the MCA25. Due to the high outcome variability, this model more accurately models the 
variation seen in human stroke and is useful in studying the effect of infarct size and location on outcomes. 
However, this high degree of variation may be responsible for masking signals in treatment studies. For 
example, Abeysinghe et al (2015) failed to detect improvement in lesion size or behaviour following a 
neuroprotective intervention in endothelin-1 MCA stroke rats, which may have been due to a 
conspicuously large variation in lesion volume.  
Another related model creates uniform lesions by applying endothelin-1 to the brain surface or 
injecting it into the cortex26.This method creates localised and well-controlled lesions, however these are 
not strictly representative of spontaneous stroke in humans. As endothelin-1 is a vasoconstrictor, this 
model produces little post-stroke oedema, an important component of stroke pathophysiology27. 
Additionally, endothelin-1 has neuronal and glial receptors that appear to cause effects unrelated to 
ischaemic stroke28–30.  
 
Embolism is a common causal event of human stroke, and the arterial introduction of microemboli closely 
resembles this in terms of pathophysiology. This method involves the injection of emboli ranging between 
50 and 400μm into the MCA or internal carotid artery. These emboli lodge, depending on their size, into the 
MCA, its major branches or smaller arteries31,32. Introduction of macrospheres into the MCA results in an 
infarct that is similar to the filament MCAo model33. As these emboli are not removed, this results in 
permanent occlusion and infarcts of highly variable size,location and clinical outcome. Variations of this 
protocol use fibrin-based emboli to induce thrombosis in cerebral vessels, more closely approximating 
stroke in humans34. One setting where this type of model is highly appropriate is in the study of thrombosis 
and thrombectomy, as the emboli behave in a similar way to endogenous thromboemboli35.  
 
Photochemical ischaemia is a highly consistent and streamlined method for producing ischaemic lesions in 
mice. This protocol involves intraperitoneal injection of Rose Bengal, a photosensitive pigment, followed by 
illumination of the cranial area overlying the required lesion space36,37. The advantages of this method are 
that it produces localised and targetable lesions, is technically straightforward, has little inter-operator 
variation in lesion size or position and is associated with lower rates of mortality than other stroke models 
see 38,39 for review. As this model does not involve the occlusion of large cerebral blood vessels, the 
pathophysiological properties of the lesion differ from others in certain aspects. This model does not create 
an extensive region of penumbra as it is the terminal vessels that are occluded. Variants of the 
photochemical ischaemia protocol using ring illumination or targeted illumination of the MCA can be used 
to simulate a penumbra40,41. This should only be a consideration for studies that attempt to characterise 
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acute stroke therapies, but should not affect the results of studies aimed at recovery of disability in chronic 
stroke. 
 
The incidence of stroke and stroke risk factors in humans increases with age, however many models of 
stroke use juvenile animals42. Not only is this less likely to provide a model that is representative of stroke 
in humans, younger animals also have a greater capacity for recovery following stroke, which may mask the 
outcomes of interventional studies43. Therefore, animal studies of therapies targeted at stroke in adult 
humans should use animals that have at least been approximately age-matched. Mice reach sexual 
maturity at 5-10 weeks of age and have an average lifespan of approximately two years44. Therefore, 
experimental stroke induction in mice should ideally take place in mice above the age of 12 months. 
However, obtaining aged animals can be cost-prohibitive. To avoid masking of results by spontaneous 
recovery, non-juvenile animals should be used. One study has validated a chronic MCAo stroke model in 
six-month old rats45, and another has characterised acute MCAo in rats aged 56 weeks46. Here, we will 
investigate using mice at six months of age. 
 
While the focus of this study is on developing a standard model of stroke, it is important to recognise that 
stroke in humans does not conform to a standard. Indeed, stroke varies in terms of lesion size, location, the 
number of foci and clinical outcomes. However, early preclinical studies rely on controlling these factors to 
accurately measure treatment response and establish causality. While a model of stroke may be conceived 
to better model the variability seen in human stroke, this would vastly increase the sample size required to 
detect a given effect size. For example, the production of highly uniform focal motor lesions would allow 
for uniformity in the measurement of behavioural outcomes, whereas a more variable model would 
necessitate measurement of less-specific clinical outcomes that may be more prone to statistical noise. 
Therefore, a standardised model of stroke with low variability in lesion parameters fits the purpose of 
testing early pre-clinical interventions for stroke. 
 
This paper aims to characterise a stroke model appropriate for assessing the efficacy of therapies targeted 
at the chronic phase of ischaemic stroke recovery. Stroke will be induced in the forepaw primary motor 
cortex of six-month-old mice by the photochemical method. In order to evaluate the applicability of this 
model to future chronic stroke studies, mice will undergo behaviour testing for nine weeks following 
photochemical infarction. Mice will be humanely killed for histological analysis and MRI at regular time 
points over the duration of the study. It is expected that the mice will undergo a certain degree of 
spontaneous recovery over the course of observation. To establish a chronic stroke model, both the 








Male C57BL6 mice aged six months were sourced from the University of Adelaide Laboratory Animal 
Services. Approval for all surgical procedures and behaviour assessment was granted by the University of 
Adelaide animal ethics committee (M-2013-166). Mice were housed in the University of Adelaide animal 
facility in enriched cages on a 12 hour light/dark cycle. Mice were given free access to food and water, 
except nights before behaviour testing when food was withheld.  
 
Photochemical stroke model 
Stroke induction was executed using a variant of the photochemical stroke model described by Watson et. 
al.36. Rose Bengal dye (10mg/mL; Sigma, R3877) was dissolved in normal saline, agitated and then filtered 
through a 0.45 micron filter (minisart, Sartorius). The Rose Bengal solution was administered to mice via 
intraperitoneal (IP) injection at a dose of 100mg/Kg. Mice were anaesthetised with 3% isoflurane in a 
sealed induction chamber, then switched to a maintenance dose of 2% isoflurane via a nose cone. A 
saggital incision was made from the interparietal bone to mid-orbital point and the scalp was retracted 
bilaterally to expose the cranium. A stereotaxic frame was used to secure the mice and locate a point 
1.5mm lateral to bregma on the side contralateral to handedness, as determined by the skilled reaching 
test. This location represents the surface anatomy corresponding to the area of cortex responsible for 
forepaw motor control on the dominant side. Ten minutes was allowed for the IP rose bengal solution to 
distribute into systemic circulation prior to illumination. A 500-570nm cold light source at an intensity of 
240 lumens was directed through a 2.5mm aperture centred on the desired lesion location. A housing was 
designed and printed to provide the aperture and couple the light source to the stereotaxic frame. The light 
source was removed after a ten-minute exposure period. Mice allocated to the sham stroke group 
underwent the procedure described above, but with the light intensity kept at zero lumens. Allocation of 
mice to stroke or sham group was randomised by computer. 
 
The scalp incision was closed and treated with mupirocin to prevent infection (Bactroban, GSK). 
Bupivacaine hydrochloride (0.5%, GSK) was provided as a 50µL epidermal injection to reduce suffering 
during recovery. Isoflurane was removed and mice were allowed to regain consciousness in a dark, warmed 
box and were provided with enriched feed. Mice were assessed three times daily for clinical signs of 
morbidity for the first week following surgery and daily thereafter until the clinical score reached zero. 
 
Behaviour testing 
Forepaw sensory motor function was assessed by the ladder rung and skilled reach behaviour tests. Mice 
were trained in both activities daily for one week prior to induction of photochemical ischaemia (Figure 1C). 
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Baseline scores were recorded on the final day of training. As food pellets were used as a reward, mice 
were fasted overnight prior to training and prior to testing days. Conduct of the behaviour tests was 
unblinded, but assessment of the behaviour tests was conducted by a blinded operator. 
 
Ladder rung 
Mice were required to cross a 45cm long horizontal ladder with rungs spaced one centimetre apart. A 
mirror was placed behind the ladder and along its length at an angle of 10o to the apparatus so that both 
the near and far limbs could be viewed from one side (Figure 1A). For each trial, mice were required to 
cross the ladder three times in succession. Each attempt was recorded with a video camera and foot faults 
were evaluated while viewing footage at a decreased frame rate. 
 
Foot fault scoring was conducted using the method described by Metz and Whishaw47. Every step for each 
forepaw was categorised as being either a total miss [0], deep slip [1], slight slip [2], replacement [3], 
correction [4], partial placement [5] or correct placement [6]. The parameters used for comparison were 
the average score per step of the stroke-affected limb and the unaffected limb. Comparisons were made 
between affected and unaffected limb scores at each time point.  
 
 
Skilled reach and determination of handedness 
Forepaw motor function was assessed in mice using a skilled reaching assembly first described by Whishaw 
et. al.48. Mice were placed in a small, dark chamber 72mm wide, 200mm tall and 78mm deep constructed 
of opaque acrylic plastic. The front of the chamber was transparent and contained a 10mm wide aperture 
in the centre. Mice were required to reach through the aperture and retrieve pellets of pasta located on a 
ledge 10mm high and 10mm from the aperture. Pellets aligned with either edge of the aperture could only 
be reached with the contralateral forepaw. 
 
During the week of daily training for this task, mice were presented with 20 pellets in both the left and right 
positions. The mice progressed from initially using both forepaws to settling on a retrieval strategy that 
used only the dominant forepaw.  
 
During assessment, mice were presented with 20 pellets in succession in the location contralateral to their 
dominant forepaw. Retrieval attempts were categorised into successes, failures with pellet contact and 
failures without pellet contact. Invalid retrieval strategies were not recorded. These included attempts to 






Mice were humanely killed with 5% isoflurane in a sealed induction box at one, three, five, seven or nine 
weeks post-stroke (Figure 1C). An incision was made from the manubrium to the umbilicus, then the ribs 
were cut bilaterally at the mid-clavicular line and the diaphragm was cut to expose the mediastinum. A 
small incision was made in the right ventricle of the heart, while PBS was infused into the left ventricle at a 
constant rate. Once all blood was displaced, 4% paraformaldehyde (PFA) in normal saline at 4oC was 
infused into the left ventricle.  
 
The brain was carefully removed and fixed in a solution of 4% PFA in normal saline for 24 hours at 4oC. The 
brain was washed in normal saline three time for 30 seconds each, then cryoprotected in a solution of 30% 
sucrose in normal saline for 24 hours at 4oC before being returned to normal saline for MRI scans. 
 
Brains were sliced into 1mm coronal sections and then snap frozen in O.C.T compound (Tissue Tek). Tissue 
blocks were then cryosectioned to a depth of 30 microns. Haematoxylin and eosin staining was carried out 
by standard protocols. Histological analysis was not conducted by a blinded operator. 
 
Magnetic resonance imaging 
Brains were placed in 15mL falcon tubes filled completely with normal saline to ensure no air bubbles were 
present. A modified transfer pipette was used to prevent movement of the brain during imaging. T1-
weighted MRI was conducted using a 1.05T small animal MR machine (Bruker, ICON Compact MRI) (echo 
time = 12ms, repetition time = 45ms, flip angle = 30o). Images were taken in the frontal plane and slices 
were separated by 0.5mm. Data were collected using Paravision 6 (Bruker) and post-processing was 




All calculations were performed using Prism (Graphpad, version 7.02). With regards to behaviour test data, 
differences between the sham and stroke groups for each time point, and between time points for each 
group, were tested by two-way ANOVA with Sidak’s correction for multiple comparisons. 
A total of 19 mice were analysed by MRI and 21 were analysed by histology. For the ladder rung behaviour 
test, six stroke and four sham mice were analysed at each time point. For the skilled reach behaviour test, 
12 mice from each group were analysed at each time point. This sample size was chosen to detect an effect 






Photochemical infarction did not cause measurable chronic sensory-motor deficits 
To characterise the long-term neurological deficit caused by photochemical infarction, a total of 24 mice 
were subject to behaviour testing. The location of the lesion in this model corresponded to the area of 
primary motor cortex associated with control of forepaw function. Therefore, the affected limbs of mice in 
the stroke group experienced a relative decrease in limb placement score in the ladder rung test from 5.329 
± 0.228 to 4.412 ± 0.459 one week post-stroke (p < 0.0001) (Figure 2A). The difference in ladder rung scores 
of the affected limbs relative to the unaffected limbs between the stroke and sham group at one week 
post-stroke was 0.13 ± 0.04 (p = 0.02). This indicates a pronounced asymmetry in forelimb sensory-motor 
function acutely following induction of photochemical ischaemia. Mice recovered rapidly, with scores not 
significantly different from baseline achieved by week three. No significant difference in ladder rung score 
between the affected and unaffected forepaws was observed at any time points later than week three. 
Mice in the sham group did not exhibit any difference in skilled reaching with either forepaw (Figure 2B). 
 
The skilled reaching behaviour test was used to further assess sensory-motor deficits in the affected 
forepaw (Figure 2C). After five days of training, mice had a pellet retrieval success rate of 0.47 ± 0.15. One 
week post-stroke, mice in the stroke group had a lower success rate than the control group, though this 
may have been a chance event as it did not reach significance. No significant difference was observed 
between groups at any other time point. 
 
Histological analysis 
To analyse the tissue-level characteristics and long-term progression of this stroke model, brain sections 
were taken from mice at regular intervals following induction of photochemical ischaemia and imaged with 
H&E staining (n≥2 per timepoint). Sections for histology were taken from the midpoint of the lesions that 
were visible in the stroke group mice (Figure 3A) and from the corresponding region in the sham group.  
 
A well-demarcated lesion was visible at seven days post-stroke(Figure 4A). This early lesion was 
characterised by a border of macrophage-like cells at the perimeter of a necrotic core containing caseating 
eosinophillic debris and sparse picnotic nuclei.  At three weeks post-stroke, the infarct core had completely 
necrosed and was eliminated during processing, leaving behind an indentation in the cortex. The size of the 
lesion had partly contracted and its peripheral surface was bordered by a layer of elongated cells consistent 
with a glial scar. By five weeks post-stroke the outer layer of elongated cells had thickened and the lesion 
had contracted further. At seven weeks post-stroke the lesion had contracted and flattened out 
considerably. A number of haemosiderin-laden macrophages were bordering the infarct. At nine weeks 
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post-stroke the outer scar layer had thickened and a greater number of haemosiderin-laden macrophages 
were present. Over time, the area represented by the infarct decreased considerably (Figure 4B). 
 
Photochemical infarction creates lesions detectable by MRI 
MRI was used to evaluate the presence, size and location of photochemical infarcts without sacrificing 
tissue (Figure 3B,C). Hyperintense regions corresponding with the location of visible cortical lesions were 
seen only in the brains of mice taken one week post-stroke. The mean volume of the three lesions detected 
by MRI at one-week post-stroke was 9.22mm3 (SD=3.51mm), or 1.8% of total brain volume. Lesions 
detected by MRI were at the location targeted by the protocol. 
 
Despite having lesions that were visually apparent (Figure 3A) and detectable on later histology (Figure 4A), 
none of the MRI results from mice at later time points showed any evidence of an infarct. None of the mice 








This study provides preliminary investigations of a potential standard protocol for producing an in vivo 
model of chronic stroke in aged mice. The data demonstrate that the photochemical infarction protocol 
creates a reproducible cortical lesion, as has been demonstrated previously with similar protocols36,37. The 
lesions produced were apparent visually and were able to be measured by MRI, which would allow multiple 
analyses for individual mice without sacrificing for histology. This model of infarct also showed a typical 
pattern of organisation on analysis by histology. Behaviour testing of animals demonstrated a decline in 
sensory-motor function of the forepaw targeted by the photochemical stroke, but only in the acute phase 
of stroke recovery.  
This study demonstrated acute, but not chronic sensory-motor deficits in the function of the targeted 
forepaw. Figure 2A shows that this experimental model of stroke resulted in a significant reduction in 
performance in the ladder rung task and that spontaneous recovery of this function occurred within three 
weeks. No significant change in performance was detected by the skilled reach behaviour test. This was 
surprising as it was expected that the isolation of the affected forepaw in this protocol would provide a 
more sensitive test of function. 
 
Functional improvement is the most important goal for potential stroke therapies and therefore a relevant 
experimental model of chronic stroke must demonstrate long-term functional deficits. The photochemical 
stroke model described here did not produce chronic functional deficits that could be detected by the 
ladder rung or skilled reach behaviour tests. There were a number of limitations to our study, which will 
inform future studies. 
        The most likely reason that the mice were able to achieve near-total recovery so quickly is that the 
lesion size was too small. Future development of this model should create a larger lesion by varying 
aperture size and illumination time. In previous studies, aperture size varied from 1.5mm50 to 4.5mm18,51, 
and larger apertures consequently resulted in larger lesions. Likewise, illumination times of 552, 1053, 1518,51 
and 2050 minutes have all been used to produce lesions in similar models. It is unclear whether varying 
illumination time within this range influences experimental outcomes. This study used an aperture of 
2.5mm and a 10 minute illumination time as we found larger apertures resulted in higher mortality, while 
smaller apertures did not produce measurable behavioural deficits. Future development of this model 
should test the effects of aperture size and illumination time on functional outcomes. 
 Notably, the skilled reach behaviour test did not detect any decline in function. Previous studies 
have demonstrated this test to be an effective test of function in stroke models 9,19,54–56. These studies took 
place in rats and infarction was induced by MCAo19,54, endothelin-19 and photochemical infarction55,56. 
However, Alaverdashvili et al57 determined that the skilled reach test was not able to detect chronic 
dysfunction in rats following photochemical infarction.  Likewise, Clarkson et. al.58 determined that the 
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skilled reach test was only able to detect dysfunction up to seven days following photochemical infarction 
in mice. As a result, it is possible that the skilled reach test is not an appropriate method for measuring 
chronic dysfunction following photochemical infarction in mice. 
 Another limitation of the skilled reach test is that there may have been a training effect, which 
could mask chronic dysfunction. While not statistically significant, pellet retrieval success rates in both the 
sham and stroke groups appeared to trend upwards over the course of the study (Figure 2C). This may 
indicate that performance in this task had not reached a stable state prior to photochemical infarction. This 
issue could be addressed by increasing the time allowed for training prior to photochemical infarction. The 
five day training schedule used in this study was suggested in the original description of the skilled reach 
test in mice59, though at least one subsequent study has increased this time to 14 days58. 
Another likely reason that this study did not detect chronic disability is the low sample size. Twelve 
mice were used in each group at each time point in the skilled reach test, which was calculated to detect 
differences in function of 25% with a standard deviation of 20%, confidence of 95% and power of 80%. Only 
six stroke group mice were used per time point in the ladder rung test. It is possible that smaller differences 
in performance of these tests were missed. Increasing the sample size to 29 per group would allow the 
tests to resolve changes in performance as low as 15%. 
 
A standard protocol for stroke must produce a lesion that is consistent in volume and location. To address 
this, preliminary MRI investigations were undertaken to image lesions at regular intervals following 
induction of photochemical infarction. Lesions were measurable, but only in the brains of mice humanely 
killed one week post-stroke. The results demonstrated that at this time point, mean lesion size was 
9.22mm3 and these lesions were located at the target area. This builds on earlier studies of the progression 
of photochemical stroke, which have demonstrated that hyperintense lesions are detectable on T2- and 
diffusion-weighted MRI as early as 90 minutes after illumination and as late as seven days60,61.  
        To ensure technical consistency, previous protocols have used a quality control process whereby a 
certain proportion of animals are removed from the study early so that lesion consistency can be confirmed 
using imaging techniques such as tetrazolium chloride or cresyl violet staining37. This results in loss of 
precious tissue samples and represents an area where animal numbers may be reduced with respect to 
ethical considerations. A previous study suggested that MRI is as sensitive as these other techniques for 
quality control of MCAo infarcts in rats62, which would support our results. As it is only necessary to confirm 
the presence and consistency of photochemical lesions once after induction, the inability of the present 
protocol to resolve lesions at later time points is not detrimental. These results are only preliminary as MRI 
studies were limited and were not conducted in live animals. However, these results do suggest that use of 
MRI to confirm photochemical infarct in mice may prevent the need to sacrifice tissue for quality control. 
        It was expected that lesions imaged in the chronic phase would appear as hypointense regions as seen 
in human stroke63, but this was not demonstrated. One reason that MRI failed to detect infarcts at later 
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time points is that only T1-weighted imaging was used. T2- or diffusion-weighted MRI may be more 
appropriate for showing regions of enhancement at later timepoints64. Gross structural abnormalities 
including cavitations and perilesional distortions should still be detectable by T1-weighted imaging. 
However, histological data demonstrated that the lesions contracted over time (Figure 4B). The lesion 
shown in Figure 3B,C representing a brain at week one post-stroke had a depth of 1.25mm when measured 
on histology, whereas the brain imaged at week three measured 0.53mm deep. The MRI protocol captured 
0.5mm slices in the transverse axis, so older lesions fell below the minimum detectable volume at this 
resolution. Use of a higher resolution MRI protocol may have been able to image lesions at later time 
points. 
Another limitation is the choice of animal used in this study. The evolution of human stroke is 
influenced by the anatomy of the brain, cerebral circulation and cranium. There is no ideal animal model 
for human stroke as the human brain is a much larger and more complex structure than any animal brain. 
Despite being by far the most common animal model of stroke43, mouse brains are more unlike humans’ in 
terms of size and complexity than are other mammals. Indeed, MCAo in mice has produced more variation 
in lesion sizes than has MCAo in rats see 29 for review. Larger, gyrencephalic animals such as sheep or non-
human primates may provide a more appropriate model for human stroke as they are closer in anatomy. 
However, these animals are more expensive to use and require a higher degree of ethical justification. A 
balance may be found in using larger animals, such as rats or sheep. 
 
Following ischaemic stroke, the brain undergoes a well-defined organisation and resolution process that is 
unique amongst other tissues. The histologic data presented in Figure 4 demonstrate that this chronic 
stroke protocol produced a lesion that underwent a similar evolution to other well-recognised stroke 
models, such as MCAo65. The lesion was initially large and showed evidence of inflammatory processes with 
extensive macrophage infiltration bordering the infarct. The necrotic debris was cleared to leave a cavity 
and a wall of elongated cells and extracellular matrix formed around the infarct. Over the course of the 
study, lesion size decreased markedly, with the resolved scar at week nine barely visible (Figure 4A,B). 
These results suggest that the methods produce an accurate model of chronic ischaemic stroke at a tissue 
level. 
It should be noted that in human stroke, lesions also occur within subcortical regions and in particular often 
have white matter involvement. The present study aimed to produce a focal lesion within the motor cortex 
as a way of reducing variability in outcome measurement. As a result, this model does not address such 
sub-cortical damage. While this is not problematic for the study of many potential stroke treatments, it 
would not be appropriate for any treatment where the proposed mechanism lies specifically in white 
matter or basal ganglia repair. For example, this model would not be suitable for the study of treatments 




Medical interventions currently available for the treatment of stroke are limited to attenuating the 
ischaemic damage that occurs during the acute phase of stroke pathogenesis. In order to develop new 
therapeutic options for stroke, an appropriate in vivo model is required. This study presented preliminary 
investigations towards the development of a standard protocol for an experimental model of chronic stroke 
that is highly reproducible, technically straightforward and biologically relevant. The protocol described 
here produced consistent lesions, was technically straightforward and caused less morbidity than other 
protocols.  
Future development of this model should investigate the use of larger apertures and longer 
illumination times to generate larger infarcts. This will ensure that the cortical target is more likely to be 
completely within the infarcted area and therefore more likely to manifest the desired functional deficits. A 
larger infarct size will also improve measurement by MRI at later time points. An increase in lesion volume 
would likely increase morbidity and unintentional mortality, but it appears that this is necessary to better 
approximate ischaemic stroke in humans. T2- and diffusion-weighted MRI techniques should be employed 
early to confirm infarction and to detect long-term changes following stroke. A larger sample should be 
analysed by this method. Stroke volume should be determined in live animals, as the goal of MRI in this 
case is to confirm infarct without sacrificing animals for that purpose. The protocol should also be tested in 
rats, as these may be a more appropriate model animal model for human stroke. Finally, a larger battery of 
behaviour tests should be employed to determine the best method of detecting chronic neurologic 
disability following stroke in rodents. 
        This study represented a starting point for the development of a standard protocol for a model of 
chronic stroke in aged mice. Further development of this protocol will enable more efficient assessment of 









Figure 1: Post-stroke forepaw sensory-motor dysfunction was assessed with behaviour tests. A) Foot faults 
were scored for both the affected (near) and unaffected (far) forepaws as mice traversed a horizontal 
ladder. Relative dysfunction of the affected forepaw compared with the unaffected forepaw was recorded 
over time. B) Mice were placed in a feeding apparatus where they were trained to retrieve pellets from a 
platform through an aperture. Handedness was determined by presenting mice with pellets in both left and 
right positions concurrently (right). Function was assessed by counting retrieval attempts for the 
dominant/stroke-affected forepaw (middle). C) Experimental timeline. Mice were trained in behaviour tests 
for five consecutive days prior to induction of photochemical stroke. Behaviour testing took place weekly 







Figure 2: Analysis of behaviour testing. Ladder rung and skilled reaching behaviour tests were conducted to 
evaluate forepaw sensory-motor function prior to induction of photochemical ischaemia and at seven day 
intervals up to nine weeks post-stroke. A) analysis of ladder rung testing in stroke group mice. Dots indicate 
mean ladder rung score. Error bars indicate SD, * indicates p<0.05. N = 6 experimental repeats at each time 
point. B) Analysis of ladder rung testing in sham surgery mice. Dots indicate mean ladder rung score. Error 
bars indicate SD, * indicates p<0.05. n = 4 experimental repeats at each time point. C) Analysis of skilled 
reaching behaviour test. Dots indicate mean successful pellet retrievals as a proportion of total attempts. 







Figure 3: A) Photographs were taken of the dorsal aspects of brains from mice in the sham group, one week 
post-stroke and nine weeks post stroke. Lesion site is indicated by *. B) Transverse and C) lateral composite 
images of MRI sections of brains from mice in the sham group, one week post stroke and nine weeks post-
stroke. Images in each group correspond to the same mouse. Representative MR images shown of n=3 





Figure 4: A) Mouse brain sections were gathered at regular intervals up to nine weeks post-stroke. These 
were examined histologically with haematoxylin and eosin staining. Images shown are representative of 
n=21 brains. B) Data points represent the infarcted area on histological sections, bold lines indicate mean 
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Chapter 6: Concluding remarks 
6.1: Project Significance 
The unifying concept behind this thesis is the need for new treatments for stroke to extend the 
therapeutic window and enhance long-term recovery. This need arises because current strategies 
for managing stroke increase survival, but fall short of reversing the chronic neurological disability 
that often results from stroke. As a result, many stroke victims live with permanent and severe 
disability, at a great cost to the individual and to the community1. Therefore, this thesis addressed 
aims relating to two overlapping paradigms of potential stroke treatment: stem cell transplantation 
and interruption of perineuronal nets (PNNs). 
The first results chapter (Chapter 2; published manuscript) tested the ability of adult human dental 
pulp stem cells (DPSC) to enhance permeability across an in vitro model of the blood-brain barrier 
(BBB). Dental pulp stem cell conditioned media were able to increase the permeability of an 
endothelial and astrocyte co-culture model BBB. This effect was found to be due to the expression of 
vascular endothelial growth factor-a (VEGF-a). This cytokine was expressed in DPSC populations and 
blockade of its receptor inhibited the ability of DPSC to induce BBB permeability. The rationale for 
this study lay in the concept of stem cell transplantation as a treatment for ischaemic stroke. Both 
direct intracerebral transplantation2 and intravascular3,4 stem cell transplantation have shown 
efficacy in pre-clinical stroke studies. Critically, it has been demonstrated that stem cells 
transplanted via an intravascular route can enter the brain parenchyma3. This is important because 
intravascular administration is much less invasive than direct intracerebral transplantation and is less 
likely to result in complications. The results outlined in Chapter 2 of this thesis elucidate the likely 
mechanism by which stem cells may enter the brain parenchyma following intravascular 
transplantation. 
Another goal of research in cell-based stroke therapy is to elucidate the mechanisms of action that 
underlie its efficacy. This was addressed by the second results chapter (Chapter 3; manuscript in 
preparation), which explored the ability of DPSC to degrade PNNs. Conditioned media samples from 
DPSC were shown to attenuate staining of PNNs in a cell monolayer and in brain slice sections. 
Conditioned media were subsequently interrogated for the presence of enzymes known to digest 
PNNs. It was found that DPSC express matrix metalloproteinase-2 (MMP-2) in its active form. This 
enzyme is known to digest aggrecan, one of the main PNN components. This study was undertaken 
to elucidate the mechanism of action of cell-based therapy in stroke. Despite showing efficacy in 
numerous pre-clinical studies2,3,5, these mechanisms have still not been fully characterised. These 
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results demonstrate that DPSC are capable of digesting PNNs through the expression of MMP-2. This 
is noteworthy because PNNs are potent inhibitors of neuroplasticity in the adult central nervous 
system and removal of PNNs creates a period of enhanced neuroplasticity6–8. Therefore, a likely 
hypothesis is that transplanted stem cells improve outcomes after stroke by enhancing 
neuroplasticity. This will help to inform the optimisation of cell-based therapies in future.  
Given that digestion of PNNs is a hypothetical mechanism of action for cell-based stroke therapy, it 
is important to understand the endogenous regulation of PNNs following stroke. This was 
investigated in the third results chapter (Chapter 4; manuscript in preparation). To the best of our 
knowledge, this study provides the most complete coverage of PNN components by 
immunohistochemistry in the cortex of mice following photochemical infarction to date. The critical 
outcomes of this study were that cartilage link protein-1, aggrecan and WFA-binding glycans were 
significantly downregulated in the region contralateral to the infarct. This may underlie a period of 
enhanced neuroplasticity that has been observed during recovery from ischaemic stroke9–11. There 
was also an enrichment of 4-O-sulfated chondroitin in the infarct border zone, which may underlie 
some of the inhibitory function of the glial scar. Understanding the endogenous regulation of the 
mechanisms responsible for inhibiting neuroplasticity in adults will contribute to the development of 
new treatments for ischaemic stroke, with adult neuroplasticity as the target. Post-stroke 
neuroplasticity may be further enhanced by disrupting PNNs artificially, either through cell-based 
therapy as we have shown, or through enzymatic digestion. 
The development of new treatments aimed at the chronic sequelae of stroke, such as those 
described above, requires an in vivo model of chronic stroke.  In the fourth results chapter (Chapter 
5; manuscript in preparation), a photochemical method was used to induce focal infarction in the 
motor cortices of aged mice. Acute, but not chronic deficits were detected by the ladder rung 
behaviour test and no deficit was detected by the skilled reach behaviour test. Infarcts were 
detected by T1 MRI at one week post-stroke, but not at later time points. Brain tissue from mice 
euthanised at regular time points up to nine weeks post-stroke was analysed by histology. These 
results demonstrated that infarcts generated by this photochemical method underwent a similar 
evolution to other stroke models12. This study was undertaken to fill the need for a standardised 
model of chronic stroke. The limitations of this study will be used to inform the future development 
of a chronic stroke model. This would provide a valuable preclinical model in which to evaluate the 
efficacy of potential treatments aimed at enhancing recovery in the chronic phase of stroke. Such 
therapies will include those targeted at enhancing neuroplasticity, such as stem cell transplantation 
and PNN disruption. 
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This thesis clarified aspects of the mechanisms of action underlying the efficacy of cell-based therapy 
for stroke. In particular, it described the interactions between DPSC and brain microstructures – the 
BBB and PNNs. Chapter 2 provided evidence towards a hypothetical mechanism by which stem cells 
transplanted by an intravascular route may gain access to their target in the brain parenchyma. Once 
at the site of action, transplanted stem cells are hypothesised to elicit a therapeutic effect through 
bystander effects. Results presented in Chapter 3 suggest that one of these mechanisms of action 
may be the enzymatic degradation of PNNs, which would therefore permit enhanced 
neuroplasticity. This concept was explored further in Chapter 4, which revealed a temporary 
downregulation of PNNs following stroke that was more significant in the contralateral hemisphere. 
These findings may underlie a period of enhanced neuroplasticity that follows ischaemic stroke and 
artificial extension of post-stroke PNN downregulation is therefore a promising therapeutic target. 
Finally, the future development of these treatment options for victims of chronic stroke requires an 
appropriate in vivo model of chronic stroke. Chapter 5 presented a preliminary study towards the 




6.2: Future Directions 
Chapter 5 outlines a preliminary study towards the development of a chronic model of 
photochemical infarction in mice. These negative results and the limitations of the study should 
inform the future development of a chronic stroke model. A study should be conducted comparing 
the effects of different illumination times and aperture sizes on infarction size and long-term 
outcomes of behaviour tests. Based on the discussion in Chapter 5, appropriate parameters would 
be aperture sizes between 2mm and 5mm, and illumination times between 5 and 20minutes. 
Additionally, a larger battery of behaviour tests should be used, though the skilled reach test should 
not be included as it appears that it is not appropriate for detecting chronic disability13,14. Sample 
size should be powered to detect smaller functional deficits; at least 29 animals should be used per 
group. T2- and diffusion-weighted MRI should be used to confirm infarct consistency at one week 
post-stroke and histological changes should be analysed post mortem.  
Stem cells have been shown to be capable of migrating across the BBB following intravascular 
transplantation3. Chapter 2 suggests that a likely mechanism for this is that stem cells enhance BBB 
permeability through the paracrine expression of VEGF-a. However, we do not provide direct 
evidence for this hypothesis. To do this, it will be necessary to replicate the study using an in vivo 
model. Stem cells should be transplanted via an intravascular route into an animal model of chronic 
stroke. It is important that this take place in the chronic phase of stroke for two reasons 1) This 
would mimic the clinical situation of humans receiving stem cell transplantation for stroke and 2) the 
acute and subacute phases of stroke recovery include innate periods of increased BBB 
permeability15,16, which would influence results. VEGF-a would then be blocked through regular 
administration of cediranib or bevacizumab. To control for the effects of endogenous VEGF-a, DPSC 
deficient in this cytokine should also be generated and used. If DPSC-derived VEGF-a is partly 
responsible for BBB transmigration, then blockade of VEGF-a signalling and use of VEGF-a deficient 
DPSC would reduce entry of the DPSC into the brain parenchyma and may attenuate the therapeutic 
capacity of intravascular stem cell transplantation. 
Building on the results described in Chapter 3, it will be important to evaluate the relative 
importance of MMP-2 expression and PNN degradation in cell-based stroke therapy. This study 
would comprise two main components. Firstly, a population of MMP-2 deficient DPSC would need to 
be developed, which could be achieved relatively easily through CRISPR-Cas9 genome editing. 
A chronic stroke model would then be treated by stem cell transplantation with DPSC or MMP-2 
deficient DPSC. The functional and neuroanatomic correlates of neuroplasticity would then be 
measured for the two groups. This could be achieved using behaviour testing along with fMRI to 
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detect function reallocation, followed by BDA injection and fibre tracing from the contralateral 
hemisphere to count midline-crossing corticospinal tract fibres. Another measure of neuroanatomic 
plasticity to consider would be to measure cortical dendrite length and dendritic tree complexity in 
both the ipsi- and contralateral hemispheres. The contribution of MMP-2-mediated PNN disruption 
to therapeutic efficacy would be determined by comparing the functional outcomes and measures 
of neuroanatomic plasticity between these two groups. 
Several concepts remain to be investigated with regards to the post-stroke regulation of PNNs and 
other inhibitory ECM components. Chapter 4 identified a temporary downregulation of aggrecan 
and PNN-associated glycans contralateral to a cortical photochemical infarction in mice. We 
hypothesised that this might be one of the mechanisms behind the phenomenon of function 
relocation, where the activities normally carried out by an infarcted cortical region are relocated to 
the homotopic contralateral region following ischaemic stroke. This is a difficult hypothesis to test as 
it would require a negative control in which endogenous downregulation of PNNs after stroke is 
blocked, and the mechanism by which post-stroke PNN modulation occurs is not yet known. One 
way to begin examining this problem would be to use retrograde axonal tracing to label midline-
crossing primary corticospinal neurons projecting to the deafferented spinal cord. Co-staining for 
aggrecan and WFA-binding glycans in the contralateral cortex would then be conducted to 
determine whether these midline-crossing neurons originate in regions where PNNs are 
downregulated. 
Work produced by the Fawcett8 and Schwab17 groups has demonstrated the critical importance of 
timing in combination therapies involving rehabilitation and enhancement of neuroplasticity through 
disruption of PNNs and inhibition of Nogo signalling respectively. Both suggest that the optimum 
treatment schedule is that rehabilitation occurs after enhancement of neuroplasticity, rather than 
concurrently. It would be interesting to determine whether this phenomenon exists in other 
potential treatment modalities. The paper produced by the Fawcett group only tested the 
combination of PNN disruption and rehabilitation on a rodent model of spinal cord injury. It would 
therefore be useful to replicate this study using a model of chronic stroke. From there, it would also 
be useful to determine whether stem cell therapy in a chronic stroke model could be optimised 
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